A Current Look at the Biological Basis of Antibody Diversity and Specificity by Barstad, Paul Arlyn
A CURRENT LOOK AT THE BIOLOGICAL BASIS 
OF ANTIBODY DIVERSITY AND SPECIFICITY 
by 
Paul Arlyn Barstad 
In Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
California Institute of Technology 
Pasadena, California 
1975 
(Submitted April 18, 1975) 
This thesis is dedicated to my wife Glenna and my daughter 
Debbie who have tolerated my long hours in the lab and helped 
so much with the preparation of this thesis, and to the Tiger 
Toads. 
iii 
ACKNO~LEDGMENTS 
I would like to thank all the people in Lee Hood's lab 
group for their helpful discussions on scientific as well as 
non-scientific subjects. Special thanks must go to Barbara 
Eaton for her cheerfulness and superb technical assistance, 
to Lee Hood for his guidance, to Jim Black for the many favors, 
and to Ray Owen for his warm friendship and encouragement. 
iv 
ABSTRACT 
Using automated protein sequence analysis of BALB/c 
myeloma proteins, the genetic basis for antibody specific-
ity~ and diversity is investigated. Studies on the N-terrninal 
regions of the heavy chains from these immunoglobulins reveal 
that a large amount of diversity must exist in the VH regions. 
Examination of the heavy and light chain sequences from mye-
loma proteins with hapten-binding activities indicates that 
the heavy chain variable region sequence correlates closely 
with all the specificities of intact molecules. The light 
chain appears to be less restricted in some specificities, 
however. The relevance of these data to the proposed mecha-
nisms of antibody diversity is discussed. 
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CHAPTER I 
THE PROBLEM 
2 
THE PROBLEM 
During evolution, about the time of the emergence of 
vertebrates, nature began to develop an active defense mecha-
nism for higher creatures to protect themselves from bacteria 
and viruses as well as perhaps from abnormal or transformed 
cells generated within their own tissues. Such a system had 
three requirements: (1) a high degree of specificity to dis-
tinguish self from non-self or normal from abnormal cells; 
(2) extensive diversity to recognize a vast number of differ-
ent foreign substances; and (3) memory, so that a second en-
counter with the same foreign material triggers a rapid and 
effective defensive response. 
Although many of the functions of the immune system in-
volve complex cellular interactions, one part called the humoral 
immune system utilizes protein molecules, called antibodies, 
which circulate and recognize the foreign materials, called 
antigens, and cause their elimination. These proteins must 
combine two functions--one part of the molecule must recognize 
and bind the antigen while another part must activate a mecha-
nism which may lyse or opsonize the cell, if it is a bacterium, 
or destroy other antigens in other ways. Mammals possess dif-
ferent classes of antibodies whose effector and stability pro-
perties are specialized for their particular location in the 
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body. Thus, immunoglobulin G (IgG) is found as the dominant 
circulating antibody, IgM makes up the largest part of anti-
body produced in a primary response, IgA is specialized to 
be stable in the gut and secretory system of the respiratory 
tract, and IgE attaches to and triggers mast cells to release 
histamine. 
The basic subunit of antibodies can be divided into func-
tional fragments. The basic functional subunit of the anti-
body molecule is shown in Fig. 1-1. It has a molecular weight 
of about 150,000 daltons and has a sedimentation coefficient 
of 7S. Enzymatic digestion of this molecule has shown it to 
consist of three regions, each with a molecular weight of 
50,000 daltons--two of which (called the Fab fragments) are 
identical and bind the antigens, and a third fragment named 
the Fe that performs at least some of the effector functions 
of the intact molecule. 
Two types of polypeptide chains make up the basic func-
tional antibody subunit. Two pairs of identical polypeptide 
chains make up the 7S subunit--two "light" chains with a molec-
ular weight of 23,000 to 25,000 daltons and two heavy chains 
ranging in size from 50,000 to 70,000, depending on the class 
of the antibody. The amino terminal half of one heavy chain 
combines with a light chain to form each Fab fragment while 
the two carboxyl halves of the heavy chains form the Fe region. 
Each polypeptide chain of an irnmunoglobulin has a variable 
portion and a constant portion. The normal antibody response 
to an antigen or antigens consists of a very heterogeneous 
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Fig. 1-1.--Structure of irnmunoglobulin 7S subunit. The 
IgG molecule shown here consists of a single 7S subunit. The 
locations of the various interchain and intrachain disulfide 
bonds are indicated. The dotted lines show the enzymatic 
cleavage points to form the Fab and Fe fragments. The shaded 
areas represent the variable regions of each chain. CHO indi-
cates the location of carbohydrate on the heavy chain. After (1). 
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collection of antibodies. The vast majority of sequence 
variation within the light and heavy chains occurs in the 
amino terminal 110 .residues or so as shown by sequence studies 
on various homogeneous immunoglobulins from human and mouse as 
well as the polypeptide subunits from heterogeneous circula-
ting IgG. These regions are called the variable regions or 
VH and VL of the heavy and light chains respectively. It is 
these regions that determine the antigen-binding specificity 
of the antibody and are the subject of this thesis. 
The remainder of the heavy chain is highly similar or 
identical in sequence from one antibody to another within a 
subclass of antibody in a single creature. The carboxyl half 
of the light chain is also constant in sequence within a light 
chain family. These two regions are called the constant re-
gions for the heavy (CH) and light (CL) chains. The V and C 
regions of the heavy or light chains are encoded by separate 
genes and thus the concept of "two genes--one polypeptide 
chain" (2). 
Three families of immunoglobulin subunits exist and appear 
to be unlinked in the mammalian genome. Two families of light 
chains exist in every mammalian immune system--kappa and lambda 
chains. These two types of chains differ greatly in the sequence in 
both the constant and variable regions. A third family codes 
for _the heavy chains. Genetic analysis of serologic markers 
on the constant regions of these chains indicates that they 
are unlinked in the mammalian genome (3). 
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The variable region dan be divided into hypervariable and 
framework residues. The three~dimensional structure of an 
immunoglobulin Fab fragment has been shown by X-ray crystal-
lography to consist of four nearly identical domains--two V 
and two C domains (4). The distal end of the VH and VL regions 
forms a cleft which binds the antigen. The light chain half 
of the cleft is formed by residues 26L-32L and 90L-96L, while 
the heavy chain half is formed by 31H-37H, 51H-58H, and lOlH-
llOH. Within a series of immunoglobulins, these regions have 
been found to be significantly more variable in sequence and 
size than the rest of the V regions. One additional region 
in each chain, 48L-55L and 84H-91H, is also highly variable 
in sequence (5,6). Accordingly, these seven areas have been 
termed the hypervariable regions. The remainder of the vari-
able region is called the framework region. 
Each antibody-secreting cell synthesizes anly one kind 
of antibody. The cell that secretes antibody molecules is 
called the plasma cell or B cell. Each plasma cell appears to 
make only one type of light and heavy chain. The variable 
regions of the light chains made by a single cell are all 
identical as are those of the heavy chain. The cell also pro-
duces either lambda or kappa chains, but not both. It is 
generally accepted now that multiple V genes exist in a 
creature and the mechanism for activation and expression of 
one of a number of variable region genes is of interest from 
a developmental standpoint as well as from an immunological one. 
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The number of different antibodies that can be made by 
a single creature must be very large. The more specific the 
interactions are between an antibody and antigen, the more 
diverse the antibody library must be in order for the creature 
to protect itself against a broad spectrum of potential patho-
gens. Thus, any factors concerning either diversity or spec-
ificity of antibodies yield information about the other compo-
nent. 
Since antibodies can distinguish self from non-self in 
many instances, they must be rather specific, analogous per-
haps, to certain . enzymes. The total antibody library must 
also recognize a large number of different antigens in order 
to keep the creature alive. The number of different antibodies 
that can be made by a single creature must then be very large 
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and 10 different specificities may be necessary and sufficient 
to keep a creature healthy. This is merely an estimate and cer-
tainly the actual number may be an order of magnitude above or 
below this figure. 
The amount of functional antibody diversity depends on 
£our factors. In order to approach estimating the total func-
tional diversity and specificity present within a creature, 
one can divide the problem into its two components: (1) how 
many different functional antibody molecules can an animal 
make? and · (2) what are the contributions of the heavy and 
light chains in determining the antigen-binding specificity 
of the molecule? The number of functional antibody molecules 
can in turn be divided into three separate questions. (a) how 
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diverse are the light chains? (b) how diverse are the heavy 
chains? and (c) can any heavy chain pair with any light chain 
(and vice versa) to form functional antibody molecules? 
While a great deal of data have been obtained concerning the 
total light chain diversity, the other three questions have 
been relatively unanswered. 
Four theories have been advanced to explain the diversity 
of antibody subunits. Since the three-dimensional structure 
of the antigen-binding site determines the specificity of the 
antibody, and since the primary structure of the variable re-
gion determines the tertiary structure, the question of the 
biological ba~is · for information storage and expression for 
antibody subunits has been a subject of interest for several 
years. Two major theories have been advanced--the somatic 
theory and the germ line theory--to explain the diversity of 
primary sequences in antibodies. 
The somatic theory (7) postulates that a limited number of 
genes for antibody variable regions are passed on in the germ 
line from parent to progeny . By this theory, the diversity of 
antibodies is generated by mutation in the soma during develop-
ment. In this theory, antibody genes are coded by a small amount 
of germinal DNA. However, almost limitless diversity can be 
generated. It would also predict a large amount of random 
sequence flexibility within antibodies that bind similar antigens. 
The germ line theory (8) postulates that all antibody genes 
are present in the germ line. This theory requires a large 
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number of variable region genes. Selection for specificity 
and diversity then occurs during the evolution of the species 
rather than during ontogeny . Subunit diversity is generated 
by expression of all the hundreds or thousands of variable 
region genes for each family. 
The two other theories that have recently arisen involve 
modifications. of germ line and somatic theories. Essentially, 
these two theories maintain that the hypervariable regions 
are under separate control for diversity from framework resi-
dues. Both of these hypotheses assume that a large (at least 
200) number of genes code for the framework residues. 
The antigen-driven somatic mutation theory (9) maintains 
that the basic antibody diversity is encoded in the germ line 
but that during expansion of the clone following antigenic 
stimulation some clones will accumulate random mutations in 
the hypervariable regions which give them a higher affinity 
for the original antigen. These mutant clones are then ex-
panded to a greater extent than the corresponding clones with 
the original antibody. While mutations in these regions prob-
ably occur, most of the mutations must·be either neutral or 
harmful and it is difficult to conceive how such a mechanism 
could have much advantage in vivo at the currently accepted 
rate of random mutation. 
The second theory in this category is called the episomal 
theory and claims that the hypervariable regions are actually 
separate genes that are spliced into the framework genes(lO). 
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Several different combinations of hypervariable genes could 
be s~liced into the same framework gene generating a tremen-
dous diversity from only a small amount of DNA. This theory 
requires "five genes--one polypeptide chain" and my data 
clearly dispute its existence. 
This thesis investigates the heavy chain diversity and 
genetic basis of irnrnunoglobulin specificities. 
These four theories of subunit diversity were based pri-
marily on data concerning the BALB/c light chains. In this 
thesis, investigations on the diversity present within the 
heavy chain subunit are reported. In addition, I have evalu-
ated the relative importance of the heavy and light chain 
amino acid sequences in determining the function (i.e., hapten-
binding activity) of an immunoglobulin. This work renders the 
episomal theory unlikely and strongly supports the concept 
of a germ line basis for antibody diversity. 
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CHAPTER II 
THE SYSTEM 
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THE SYSTEM 
Ideally, to approach the questions concerning antibody 
diversity one would like to study a series of antibodies 
made in a single individual in response to a single antigen. 
In practice, however, such antibodies can normally only be 
studied by micro methods such as - isoelectric focusing since 
there is too little of any antibody species for sequence anal-
ysis. While such a study can give insight into the hetero-
geneity of an immune response, (11) it cannot give any data on 
the genetic relationship of the various molecules or their 
subunits. 
Relatively restricted antibodies may be induced using 
special immunization techniques. Two examples of relatively 
large amounts of homogeneous antibodies exist. The first is 
the production of large quantities (up to sq mg/ml of serum) 
of antibodies of restricted heterogeneity (apparently two or 
three homogeneous antibodies) to bacterial polysaccharides in 
rabbits by repeated immunization (12). Since rabbits are not 
inbred, however, the genetic relationships of these antibodies 
can only be meaningfully evaluated against the other few anti-
bodies available in large amounts from that individual animal. 
Recently it has been possible to raise large amounts of 
restricted antibodies in the BALB/c mouse to the hapten 
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p-azophenylarsonate by hyperimmunization with this antigen 
coupled to a carrier followed by induction of an ascites 
tumor (13). The ascites tumor is a free-growing tumor in the 
peritoneal cavity and results in the accumulation of 15 ml or 
more of fluid in that area which contains the immunoglobulins 
in concentrations similar to that found in the serum. This 
approach allows one to do a series of experime~ts within a 
single genome (BALB/c) but ~lso has a couple of disadvantages. 
First, since each mous.e may respond differently to the 
antigen, the antibodies from many mice should not be pooled 
or one will only be 'detecting the major sequences of the res-
ponse. Second, the antibodies made within a single mouse are 
usually heterogeneous as judged by isoelectric focusing. 
While such antibodies can be purified by preparative isoelectric 
focusing, many minor bands are present in too small amounts 
to analyze, and thus the total diversity within a specificity 
cannot easily be determined. 
Multiple myeloma offers virtually unlimited amounts of 
homogeneous proteins in the BALB/c mouse. A type of cancer, 
known as multiple myeloma, results in the transformation and 
subsequent proliferation of a single plasma cell until its 
homogeneous immunoglobulins make up to 95% of that found in 
the circulation. 
These plasmacytomas may be induced in the inbred strain 
of mouse, BALB/c(l4,15).Such an induction program involves in-
jection of 1 ml of mineral oil or pristane intraperitoneally 
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at 60-day intervals. Within six months, over 60% of the BALB/c 
mice develop myeloma tumors which are then transplantable to 
other syngeneic animals. 
These proteins are called immunoglobulins rather than 
antibodies since they were not produced in response to stimu-
lation by antigen. The mineral oil apparently provides a 
good environment for the transformation and subsequent pro-
liferation of plasma cells in the gut. The transformation 
event seems to occur in any random antibody-secreting cell in 
the gut area since sequence analysis on these proteins has 
shown them to be very diverse. 
The tumors are usually named by four letters followed 
by a number. The letters reflect the type of inducing agent, 
as in Mineral Oil Plasmacytoma (MOPC), or person or place of 
induction, e.g., Salk= Sand Weigert= W. The number of 
the tumor is assigned by the originator. 
The myeloma proteins are an excellent system for study-
ing immunoglobulin structure. Myeloma immunoglobulins are 
the products of aberrant cells--tumors that are not respond-
ing to antigen but simply growing, dividing, and secreting 
a protein product. Early studies indicated the myeloma pro-
teins in humans did not have any detectable antigen-binding 
activities and it was questioned how applicable studies on 
these immunoglobulins were to normal antibodies. Recent 
work, however, has shown the BALB/c myeloma proteins to share 
the same structures and binding characteristics as normal 
antibodies. 
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The human and BALB/c rn:yeTorn:a immunoglobulins are dif,.... 
ferent in many respects. Much of the early work on immuno-
globulin structure was done on myeloma proteins from human 
patients. In humans, multiple myeloma appears spontaneously 
in patients usually about 50 years of age and progresses for 
a few years resulting in the death of the patient . Large 
amounts of homogeneous protein may be obtained from the indi-
vidual during the course of the disease. Human myeloma pro-
teins exhibit the same kappa and lambda ratio as the circulating 
IgG in normal humans. These proteins also appear to possess 
all the heavy chain constant regions (which determine the class 
of the antibodies) and, indeed, were instrumental in the de-
tection of some of the rare classes and subclasses of normal 
human antibodies. While these proteins share structure in 
the constant regions with normal immunoglobulins, very few of 
these proteins have been found to bind specifically to any 
hapten . 
The human population is extremely polymorphic and vari-
ation in the structure of the human myeloma proteins from one 
patient to another may be due to either differences between 
several genes within the same individual or to a polymorphism 
between the individuals. It is not possible to evaluate which 
of these two factors is most important in the observed human 
immunoglobulin variability. 
The BALB/c mouse is a highly inbred creature, on the 
other hand. Animals of this strain have been inbred to the 
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extent that all BALB/c mice must have the same genome except 
for a few spontaneous mutations which may have occurred 
recently. If 100 myeloma tumors are induced in 100 different 
BALB/c mice, then we are looking at 100 separate immuno-
globulins which are products of the same genome. It is anal-
agous to being able to isolate 100 different homogeneous anti-
bodies from the same individual. Since these mice are highly 
inbred, a given tumor may be transplanted to many other BALB/c 
mice where it will continue to grow and produce virtually unlimited 
amounts of the original homogeneous immunoglobulin. 
The BALB/c myeloma proteins, like their human counter-
parts, possess many of the same constant regions as the normal 
antibodies of the animal. Both kappa and lambda light chains 
have been found. The BALB/c myeloma proteins include IgM, 
IgA, IgG-1, IgG-2a, IgG-2b, and IgG-3. No IgD or IgE has been 
reported. 
Unlike their human counterparts, however, the BALB/c 
proteins often show a relatively high specific binding to 
various haptens, particularly antigens present on gut flora 
and dinitrophenyl proteins. Binding constants for these hap-
tens range from lo S to 10 7 M-l. Th BALB/ 1 t . e c mye oma pro e1ns, 
therefore, appear to represent the products of functional anti-
body-producing plasma cells which have been expanded by trans-
formation. 
The BALB/c myeloma proteins also differ from the human 
myeloma proteins in that while most of the human proteins are 
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IgGs, the vast majority of those in the BALB/c are IgAs. 
Since most of the human myelomas are found in the bone marrow 
(where mostly IgG is produced) and the BALB/c tumors arise in 
the peritoneal cavity (where the majority of immunoglobulins 
are IgAs) this is not surprising. 
Many of the BALB/c myeloma proteins exhibit hapten-
binding affinities analogous to antibodies. One criticism 
of the study of myeloma proteins as a model for antibodies 
was that they lac-ked a well-defined hapten-binding specificity. 
The discovery that MOPC 315 had a binding constant for dini-
7 -1 trophenyl of 10 M demonstrated that myeloma proteins could 
have a high affinity for a hapten(l6). Extensive screening 
programs were conducted and it was found that 5% to 10% of 
the hundreds of tumors examined bound to a few common antigens 
including dinitrophenyl, phosphorylcholine, and various carbo-
hydrate moities. Since these tumors arise in the peritoneal 
cavity, it is reassuring / that many of these haptens are found 
on gut flora indicating the gut associated lymphocytes have 
probably been clonally expanded by these antigens prior to trans-
formation. 
Several different carbohydrate specificities have been 
found . Six myeloma proteins specific for f3(1-+6)-n'-galactan 
have been characterized by N-terrninal sequence analysis. Both 
a(l-+3) and a(l-+6) dextran-binding BALB/c myeloma immunoglobu-
lins have been studied in regard to the size of their binding 
site and serologic properties. Two levan specificities, 
f3(2-+l) and f3(2-+6), have been studied by sequence analysis also. 
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Eleven BALB/c myeloma proteins have been found which bind 
phosphorylcholine. This binding specificity was characterized 
by screening large numbers of myeloma proteins against gut 
bacteria antigens. These 11 proteins form a precipitin band 
against Pneumococcal c polysaccharide that can be inhibited 
by adding free phosphorylcholine to the system. The binding 
constants determined by equilibrium dialysis for phosphoryl-
choline range from 10 4 to 10 5 M~ 1 for the five tumors charac-
terized. 
Serological studies have shown many of these phosphoryl-
choline-binding tumors to be highly similar, if not identical, 
in their variable region structure to the normal phosphoryl-
choline-binding antibodies made in BALB/c. Antisera were made 
to several of the phosphorylcholine immunoglobulins by injec-
ting them into A/He strain mice. After appropriate absorptions 
to remove non-specific antibodies, the antiserum made against 
each myeloma protein was assayed against over 100 other BALB/c 
immunoglobulins. The specific determinants recognized in this 
manner are called "idiotypic" determinants (from the Greek 
work "idios" meaning "one's own"). Since all these proteins 
are IgAs and have kappa chains, they all contain the same con-
stant regions and thus the idiotypic determinants must be 
located on the VH or VL or on a combination of the two V regions. 
When the heavy and light chains are separated and checked for 
the idiotype of the intact molecule, neither subunit has much 
activity indicating that a large portion of the idiotypic 
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determinants require heavy and light chain interaction (17) . 
The degree of specificity of the antiidiotypic antisera is 
often a problem . Some of the determinants recognized by the 
antisera may be shared by other heavy and light chain pairs. 
If, however, two proteins are able to compete equally well 
against an antiserum to one of them and vice versa, the two 
molecules must have all the idiotypic determinants in common, 
suggesting a great deal of sequence similarity, if not iden-
tity. 
Seven of the phosphorylcholine-binding myeloma proteins 
have been found to be idiotypically identical (15,17). These 
proteins, Tl5, H8, 299, 563, 5107, Y5170, and Y5236 are said 
to have the Tl5 idiotype. Sher and Cohn (18) have shown that 
the majority of the antibody to phosphorylcholine made in the 
BALB/c mouse also has the Tl5 or Sl07 idiotype. This suggests 
structural similarity or identity between the variable regions 
found in BALB/c myeloma proteins and antibodies. 
The a(l+3) dextran-binding antibodies show similarity in 
idiotype and sequence for myeloma proteins. A second idiotype, 
one in which the myeloma proteins bind a(l+3) dextran, has been 
studied in the BALB/c mouse (19). Antiidiotypic antisera made 
to these myeloma proteins reacts with idiotypic identity with 
the normal a(l+3) dextran antibodies produced in the BALB/c. 
This a(l+3) dextran antibody can be produced in quantities suf-
ficient for sequence analysis. The myeloma heavy chains from 
molecules which bind a(l+3) dextran have a very unique sequence, 
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vastly different from the normal pooled sequence(20) (Fig. 2-1). 
Although the protein was somewhat insoluble in various solvents 
(including TFA), I . was able to do a preliminary sequence analy-
sis of the pooled heavy chains from BALB/c antibodies raised to 
a(l+3) dextran on some material supplied by William Geckler at 
the Salk Institute. This sequence had the same unusual resi-
dues at all the detectable positions as J558, a myeloma protein 
which binds this polysaccharide, implying that at least some 
myeloma and antibody pools share the same variable region se-
quences (Fig. 2-1). 
Myelorna proteins may be better for studying antibody :di-
versity than bona fide antibodies. In addition, we have sequenced 
nearly the total variable regions from a series of heavy chains 
from molecules that bind phosphorylcholine. These chains ex-
hibit limited heterogeneity. The nature of the variation is 
such that if we pooled all seven chains together, however, it 
would be very easy to mistake it for a single sequence with 
present day technology. Pooled sequences in general cannot be 
as absolute as claimed by some and indeed, it seems that the 
myeloma system is, in fact, better than normal antibodies for 
examining antibody diversity. 
The myeloma immunoglobulins probably do not represent the 
total antibody (or immunoglobulin) diversity of the BALB/c mouse. 
This immunoglobulin population likely represents clones which 
have been preferentially expanded out by gut antigens prior to 
transformation. Undoubtedly, we are looking at only a subset 
of total diversity of antibodies. It appears to be a very 
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Fig. 2-1.--N-terminal sequences of BALB/c heavy chains 
from antibodies to a(l+J) dextran, pooled serum antibodies, 
and a(l+J) dextran-binding myeloma protein J558. Single letter 
abbreviations are: A, alanine; B, asparagine or aspartic 
acid (asx); C, cysteine; D, aspartic acid; E, glutamic acid; 
F, phenylalanine; G, glycine; H, histidine; I, isoleucine; 
K, lysine; L, leucine; M, methionine; N, asparagine; P, praline; 
Q, glutamine, R, arginine; S, serine; T, threonine; V, valine; 
W, tryptophan; Y, tyr?sine; Z, glutamine or glutamic acid (glx). 
Boxes indicate residues shared between J558 and antibody to 
a(l+J) dextran that are not found in the normal pool. Data 
from this thesis. 
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Position 1 5 10 15 
J558 E V~L~E s G[;)L v K p G~S~ 
a.1,3 Dextran z V Z L Z Z s G P Z L v ? p G A S V 
Normal Pool VH E V K L L E s G G G L v Q p G G S L 
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diverse subset, but it is not clear how much more diverse 
the total immunoglobulin variability may be. 
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CHAPTER III 
THE TOOLS 
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THE TOOLS 
The vast majority of the data in this thesis were gener-
ated by four machines in our laboratory. Two of these machines 
are Beckman 890A sequencers which were updated two years ago 
to resemble the 890C that Beckman still markets. The third 
machine is a Hewlett-Packard gas chromatograph (GC) Model 7600 
which is used to identify about half of the amino acids. 
Finally, we have a Durrum D-500 amino acid analyzer which anal-
yzes 10 nanomoles or less of amino acids and quantitates the 
hydrophilic amino acids (which the GC does not) as well as the 
hydrophobic ones. Since the major portion of my time was spent 
in combat with these semi-reliable creations, I feel it only 
just to describe their salient features so that a reader un-
familiar with sequencing can more readily understand, interpret, 
and appreciate the data. 
Edman reaction. The heart (or hearts) of the laboratory 
is the Beckman protein/peptide sequenator. This device employs 
essentially the same chemistry as that developed by Pehr Edman 
20 years ago (21) appropriately termed the Edman reaction. (Fig. 3-1) 
The reaction degrades polypeptides from their N-terminus one 
step at a time. By analyzing which amino acid derivative is 
generated at each cycle of the degradation one can unequivo-
cally establish the primary structure of the polypeptide. 
27 
Fig. 3-1.-~Chemistry of the Edman degradation. 
See text for details. 
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The Edman reaction begins by coupling phenylisothiocyanate 
(PITC) to the free N-terminus of the polypeptide (Step 1). 
This reaction ~s carried out at pH 9 or higher as it requires 
the unprotonated form of the amine group to form the phenyl-
thiocarbamyl (PTC) derivative. 
Cleavage of the PTC-peptide at low pH generates the 
2-anilino-5-thiazolinone derivative of the first amino acid 
and a peptide one amino acid shorter than the original (Step 2). 
Anhydrous trifluoroacetic acid (TFA) and heptafluorobutyric 
acid (HFBA) are the most commonly used reagents for this cleavage 
reaction. 
The final step is carried out manually and converts the 
2-anilino-5-thiazolinone derivative to a more stable amino 
acid phenylthiohydantoin (PTH) (Step 3). This is normally 
accomplished at 80° in aqueous HCl. Analysis of PTH deriva-
tives by physical-chemical means allows one to determine what 
the original amino acid was at the N-terminus. 
Beckman sequenator. A sequenator does not give you a se-
quence, it merely takes the protein apart one step at a time 
from the N-terminus and delivers the substituted amino acids 
present at each step into a fraction collector tube for analysis 
by the other instruments and thin-layer chromatography. The 
instrument employs a precision ground cup which spins at 600 
or ~200 rpm on whose inner walls the protein is spread from 
solution in a thin layer. The sequencing procedure consists 
of washing chemicals over the protein surface in such an order 
as to perform the Edman degradation. 
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The delivery of chemicals and application of vacuum and 
nitrogen to the reaction cup are controlled.by a programmer 
which reads a paper tape that has been appropriately punched 
by the operator. A sequencer program consists of 35 or more 
steps during which different valves are activated for a period 
of time as designated by the tape. 
The valves control the delivery of the reagents and sol-
vents used by the 890 sequenator. Three reagents, PITC (Rl), 
coupling buffer (R2), and HFBA {R3) and two solvents, benzene (Sl) 
and butyl chloride (S3) are used for each cycle. Since any impur-
ities in the chemicals interfere with the degradation, all 
solvents and reagents must be extremely free of contaminants; 
thus only sequencer grade chemicals are used. 
The main parts of the reaction program are: (1) addition 
of 5% PITC in heptane and drying off heptane (Rl}; (2) addition 
of coupling buffer pH 9.5 (R2) followed by a 30-minute reaction 
time during which the protein dissolves in the R2 and the PITC 
couples to the N-~erminus of the polypeptide; (3) after drying 
off the R2, benzene (Sl) is washed over the sample to remove 
the reaction byproducts and non-volatile components of the 
buffer. Vacuum is applied to the reaction cell to remove the 
Sl. The phenylthiocarbamyl amino acid is then cyclized in 
heptafluorbutyric acid (HFBA) (R3) for seven minutes at 57°. 
HFBA is used instead of the original TFA to prevent evapora-
tion and drying during cleavage. The PTC amino acid is then 
extracted in ·2 ~l of butyl chloride (S3) an~ delivSred to · 
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a fraction collector tube. The protein sample is dried down, 
the fraction collector advanced one step, and the whole pro-
cess begins again. 
All of my automated sequencing was done using one of two 
programs on the 890. Early work was done using a standard 
Quadrol D program. Quadrol is the Beckman trade name for 
N,N,N',N'-tetrakis (2-hydroxypropyl) ethylenediamine and is 
used in R2 as the buffer. The Quadrol D program includes two 
cleavages and two extractions (one delivers to the fraction 
collector and a second to waste) per cycle. This program 
suffered from a high degree of washout and acidolysis, making 
residues out 30 residues or more difficult to interpret. 
The DMBA program was designed by He-rm.odsCln et al (22) and 
employs N,N-dimethylbenzyl amine (DMBA) with propanol and water 
as the coupling buffer (12:40:48) at pH 9.4. This program 
uses a single cleavage and extraction for each cycle and gives 
far better results than the Quadrol system. 
If each reaction is only 98% efficient, a noticeable lag 
builds up in the s~quence after 10 or more steps. This lag can 
be corrected for mathematically on a homogeneous protein. 
Ideally, of course, one could make his reaction conditions 
such that 99.9% efficiency or better was obtained and thus 
hundreds of cycles could be performed from the N-terminus 
until the entire sequence was finished. Needless to say, this 
is not yet possible for the reasons I will discuss below. 
Probably the greatest problem encountered in protein se-
quencing is the build up of background during the run. Exposure 
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of the protein to HFBA at 57° causes a small number of appar-
ently random breaks due to acidolysis. Each break in the poly-
peptide generates a new N-terminus that begins sequencing along 
with the main region of interest. Random acidolysis usually 
results in the background building up so rapidly that by step 
25, the residue present at each step is often not the major 
component in the analysis. One then has to resort to net 
change in the quantity of each amino acid from one step to the 
next to determine the sequence far out in the chain. Even 
this approach often yields questionable results out farther 
than 40 residues from ihe original N-terminus on a protein. 
Since acidolysis generates background by breakage in the poly-
peptide chain, obviously the shorter the chain, the less the 
background, and peptides should yield better data and indeed 
they do, except that they are beseiged by a problem of their 
own, namely "washout". 
washout is a problem generated by small peptides with 
PITC coupled to them. They are somewhat soluble in benzene 
and butyl chloride and thus when the peptide is washed with 
these solvents, a certain amount of peptide leaves the reac-
tion chamber. The amount of peptide being lost at each step 
increases as the peptide gets shorter and by the time 
three or four residues are left, usually the peptide is all 
gone. The amount of washout depends upon the composition of 
the peptide, of course, and rarely certain long ' peptides can be 
sequenced to the penta peptide stage or better. As a rule of 
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thumb, however, one should not expect to be able to do more 
than half of a random peptide with the present day spinning 
cup technology. 
Other reactions including O+N acetyl migrations on acetyl-
ated hydroxy amino acids and a7$ peptide shifts at aspartic 
acid and aparagine residues apparently cause some blockage of 
the N-terminus when these residues are encountered. 
Other problems exist in the automated Edman degradation 
but by far these are the most limiting. Given a functional 
sequenator then, one can hope to turn out 40 or more steps 
for analysis at the current rate of 15 steps per day on 10 
to 15 mg of protein. 
Conversion procedure. Since the amino acid thiazolinone 
is relatively unstable, it must be converted to the more stable 
phenylthiohydantoin (PTH). This is done by adding 200A lN HCl 
to each tube after the butyl chloride has been dried off under 
nitrogen. Each sample is heated to 80°c for ten minutes in a 
temp-block, cooled slightly, and then extracted twice with 
750A of ethyl acetate. Vigorous vortexing is required to thor-
oughly mix the HCl and organic phase to insure complete removal 
of the PTHs. (PTH norleucine is added to each sequenator tube 
in the sequenator to normalize for any handling losses.} Since 
the ethyl acetate-aqueous partition is done at low pH, any 
charged PTHs, i.e., histidine and arginine, remain in the aqueous 
phase and must be analyzed for separately. The 1.5 ml of ethyl 
acetate is then dried down under nitrogen, redissolved in 50 µl 
34 
Fig. 3-2.--Flow diagram for analysis of various amino 
acids generated during automated sequence analysis. The per-
centage of the organic phase sample required for each analysis 
is indicated. 
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of ethyl acetate, and transferred to a gas chromatography vial 
for injection into the gas chromatograph (GC). 
Gas chromatograph. The Hewlett-Packard 7600 gas chroma-
tograph is a modular affair composed of a separate plug in 
chassis for each function required. Thus, the oven is separate, 
as is the recorder, temperature programmer, signal amplifiers 
(electrometer), auto injector and injection control modules. 
This offers one the chance to design a gas chromatograph to his 
needs. 
The GC is used to monitor the sequencer run while it is 
in progress. Fortunately, each GC sample can run in 25 or 30 
minutes and the auto injection device can hold 17 samples, so 
with a visit to the laboratory around midnight, one can process 
up to 48 steps per day. 
In order to operate the gas chromatograph, one merely has 
to position the first sample under the syringe in the auto 
injection device, push the reset and run buttons and the GC 
does the rest. After vigorous purging of the syringe to re-
move any air, 2.5 µl of sample are injected into the sample 
column. The syringe is then washed with several volumes of 
ethyl acetate. A typical run includes six minutes of iso-
thermal operation at 185° followed by a 15° per minute rise 
to 210° and a ten-minute hold at that temperature. At the 
0 
end of that period, the GC oven cools back down to 185 and, 
after a short delay, injects the next sample. Two identical 
columns are used in this instrument--one for the sample and 
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one for reference~-and the recorder display reflects the difference 
between the output of these two columns. 
Only hydrophobic amino acids pass though our six-foot 
DC-560 columns (23)and are analyzed in the flame ionization 
detector. Thus, the amino acids alanine, serine, glycine, 
valine, threonine, praline, leucine, isoleucine, norleucine, 
methionine, phenylalanine, tyrosine, and tryptophan can be 
assayed. The results are semi-quantitative in the one nano-
mole range, but this vastly improves as the sample load in-
creases. Also, some amino acids are more stable than others 
as can be seen by the standard. (Fig. 3-3) Serine and tryp-
tophan are particularly troublesome residues that refuse to 
show up on the chromatogram occasionally if the sample size 
is small. SCM-cysteine also appears as serine on the GC and 
its analysis requires radiolabelling with 14c iodoacetamide 
prior to loading in the sequenator and counting the sequencer 
steps in a scintillation counter (Fig. 3-4). 
Thin-layer chromatography. Before hydrolysis of the other 
95% of the sample back to amino acids for analysis on the Durrum, 
it is necessary to distinguish glutamine from glutamic acid and 
asparagine from aspartic acid, since the hydrolysis causes 
deamidation. A thin-layer chromatography on silica gel plates 
coated with fluorescent indicator using a solvent composed of 
benzene: acetic acid (9:1) is used for this purpose (24). After 
removal of the solvent in an 110° oven, the plate is sprayed 
with a 1% solution of ninhydrin in acetone which upon heating 
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Fig. 3-3.--Gas chromatogram of hydrophobic amino acid 
PTHs. Approximately one nanomole of each PTH was injected 
into the DC-560 column. The program was 185°c for six minutes, 
then increased at 15° per minute to 270° and held at that tem-
perature for 10 minutes. 
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. 3 4 . f . . 14 b Fig. - .--Detection o Cysteine using C S-car oxy-
methylation. Two percent of each organic phase from sequencer 
steps 11 to 15 from H8CN1C was dissolved in 5 ml Aquasol and 
counted for ten minutes in a Beckman LS-lOOC scintillation 
counter. The Cysteine residue is at position 13. 
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0 to 110 C for five minutes, causes glutamic acid and glutamine 
PTHs to show up bright green, while aspartic acid PTH is red 
or violet, and asparagine is yellow. Also giving colored 
products in this system are alanine (violet) , glycine (orange) , 
tyrosine (yellow), and tryptophan (dull yellow) (Fig. 3-5). 
Hydrolysis of PTHs. Hydrolysis of the PTHs back to the 
amino acids is accomplished in a dessicator in 57° Hydroiodic 
acid flushed with N2 and sealed under vacuum which is put in an 
autoclave for 18 hours at 124°(25). This procedure destroys 
cysteine and serine which give alanine in the process, converts 
threonine to alpha amino butyric acid (ABA), destroys methionine, 
converts tryptophan to gly and ala, and racimizes PTH-isoleucine 
to isoleucine and allo-isoleucine. Since histidine and arginine 
are left in the aqueous phase during conversion, only 11 amino 
acid peaks (counting ile and allo-ile as one) are of interest 
on the Durrum. 
Durrum D-500 amino acid analyzer. The Durram D-500 amino 
acid analyzer was truly a breakthrough when it first entered 
the market three years ago. It cut analysis time from 3-4 
hours to 1 or 2, increased sensitivity by an order of magnitude, 
and added its own data processing unit in the form of a PDP-8 
computer. It employs a single column sulfonated polystyrene 
resin which separates all the amino acids normally encountered 
in acid hydrolysates. It also employs two photometers--one at 
440 nm for praline, the other at 560 nm for the ninhydrin reac-
tion products of all other amino acids . 
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Fig. 3-5.~-Relative positions and colors of PTH amino 
acids on silica gel coated with fluorescent indicator. Rele-
vant PTH AA are indicated. 
Solvent 
Front 
Direction 
of 
Chromatography 
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~-------
0 
0 
8 
Met - yellow 
Ala - purple 
Gly - orange 
Trp - yellow 
O Glu - green 
0 Tyr - yellow 
Q Asp - purple 
Q Gln - green 
Q Asn - yellow 
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The sample is loaded in 40 µl or less into a stainless 
steel and teflon cartridge, called a shu, and rolled down the 
sample chute. When the run is initiated, the analyzer flushes 
the last shu, ejects it by pneumatic pressure, and aligns the 
next shu by the injector. The sample is injected in buffer A 
and this buffer is pumped through the column until alanine has 
been eluted (Fig. 3-5). Buffer Bis pumped next and continues 
until tyrosine comes off and then buffer C is used for histidine, 
lysine, and arginine. After the analysis, the column is re-
generated with NaOH and the procedure beings again. 
Resolution of threonine and serine is the most difficult 
task for this system and if one requires good separation of 
these two amino acids a two-hour program is required. Since 
HI hydrolysis destroys these two amino acids, however, the buf-
fer pumping rate can be increased and also since arginine is 
left in the aqueous phase, we can stop the run after lysine 
(and save 12 minutes per analysis) allowing us to run a sequen-
ator sample in 60 minutes. 
Figure 3-6 shows a typical Durrurn chart from step 20 of 
a light chain, Tl5L. All significant peaks for a sequencer 
analysis are indicated by the three-letter abbreviations above 
each peak. This is a 72-minute analysis and includes arginine. 
The insert shows the mole percent data for each peak as com-
puted by the PDP-8. Nor is norleucine and ABA is a-amino 
butyric acid. 
Figure 3-7 illustrates the gradual decline in the signal 
to noise ratio as the sequencer run progresses. Two sets of 
Durrum analyses from Tl5 light chain run are illustrated. 
46 
Fig. 3-6.--Durrum chromatogram from a light chain, TlSL. 
All significant peaks are indicated with the three-letter 
abbreviations. The mole percent data computed by the PDP-8 
for each amino acid are shown in the insert. The order of 
elution of the peaks is from left to right and one inch on 
the chart paper equals five minutes. 
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Fig. 3-7.--Representative data from cycles 20 and 30 on 
a Tl5 light chain. The relative amount of each amino acid as 
determined by the Durrum D-500 amino acid analyzer is shown 
by the mole percent figures. The prominent residue from the 
gas chromatography analysis of these samples is indicated on 
the line marked GC. The line marked Seq indicates the deter-
mined amino acid sequence in these two regions. As is apparent, 
the sequence around step 30 is slightly less obvious and more 
lag exists here than at step 20. These data were obtained on 
10 mg of light chain using the DMBA program. 
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Step # 19 20 21 29 30 31 
Asx 6.3 7.7 6.5 6.9 7.7 8.2 
Glx 6.7 7.8 7.1 9.9 8.7 8.8 
Pro 4.4 4.2 4.6 5.0 4.2 4.2 
Gly 6.0 7.1 6.3 6.7 6:9 6.9 
Ala 15.8 16.1 17.6 17.6 20.9 27.0 
ABA 6.4 19.4 7.9 5.0 4.7 5.6 
Val 20.7 8.6 4.3 4.0 3.7 4.1 
AI + Ile 3.2 4.3 23.0 3.7 3.5 4.0 
Leu 7.0 7.7 7.3 17.0 11.4 9.8 
Nor 4.8 5.8 5.0 5.4 6.0 6.8 
Tyr 4.0 4.9 4.6 5.5 12.6 8.8 
Phe 2.8 2.9 2.8 3.4 3.4 3.5 
Lys 10.5 3.8 4.0 3.6 4.8 4.2 
GC Val . Thr/ProLeu/Ile Leutle Tyr Ser 
Seq Val Thr Ile Leu Tyr Ser 
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One is from 19 to 21 and the second from 29 to 31. As can be 
seen some amino acids are more obvious than others causing 
questionable results at some positions far out in the sequence. 
The Durrum analyzer is a high pressure system and has the 
normal tendency to develop leaks, usually in the injection valve 
or around the ram. A leak is indicated by peaks running late 
on the chromatogram. Periodic inspection and tightening keeps 
this problem to a minimum. Sample quantity is important since 
the recorder can only be set for one of five linear scales 
and too little sample gives poor quantitation while too much 
drives the peaks off scale, also ruining the quantitation. 
Even with these problems the Durrum can operate effec-
tively with such low sample loads (2.5 nm full scale on recorder) 
that usually half of the sample or less is required per anal-
ysis and therefore, any step can be rerun if necessary. 
This is how automated sequencing is done in our laboratory; 
start to finish requires about one week to sequence 40 residues, 
providing all the equipment is operational. After the first 
one hundred conversions, the work lacks excitement but the data 
obtained give insight into key biological questions, obtainable 
in no other manner. In the last few years, it has provided 
us with data relevant to the biological basis of antibody diver-
sity and specificity, the subject of this thesis. 
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CHAPTER IV 
The Heavy Chain Diversity 
The publication in this chapter is from the Proceedings 
of the National Academy of Science, USA. It is repro-
duced here with their permission. 
Reprinted from 
Proc. Nat. Acad. Sci. USA 
Vol. 71, No. 10, pp. 4096-4100, October 1974 
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:Mouse Immunoglobulin Heavy Chains Are Coded by Multiple Germ Line 
Variable Region Genes 
(amino-acid sequence/sequenator/BALB/c rnow;e/hapten binding/selection) 
P. BARSTAD*, V. FARNSWORTH*, M. WEIGERTt, ).I. COHNt, AND L. HOOD* 
*Division of Biology, California Institute of Technology, Pasadena, Calif. 91109; t Institute for Cancer Research, Philadelphia, 
Pennsylvania 19111; and t Salk Institute, San Diego, California 92112 
Communicated by Ray D. Owen, June 20, 1974 
ABSTRACT The N-terminal 20 residues of 13 heavy im-
n1unoglobulin chains fro1n 1nyelo1na proteins of the 
BALB/c inouse are co1npared with the same residues of 
15 other heavy chains described in the literature. Sixteen 
of 28 sequences are different fron1 one another. These pro-
teins fall into four major sets, with 18 of the proteins in the 
largest set being further divisible into at least five subsets. 
This pattern of diversity suggests there are at least eight 
germ Jine genes coding for the variable regions of '.lnouse 
heavy chain. J\.lany of the irn1nunoglohulins fro1n wl1ich 
these heavy chains are derived exhibit binding activity for 
~·arious haptens. The differing hapten specificities are 
closely correlated with distinct primary an1ino-ucid se-
quences. 
An understanding of the genetic mechanism responsible for 
antibody diversity is one of the most intriguing problems in 
modern immunology, for its resolution may provide insights 
into the problems of information storage and expression in 
other complex systems (1, 2). Two alternative hypotheses for 
antibody diversity have been proposed-the germ line theory 
suggests that diversity arises in antibody genes during the 
evolution of the species, whereas the somatic theories propo~e 
that antibody diver:;ity is created anew during the develop-
ment of each individual by somatic mutation (1-3). Insights 
into the nature of this problem have come, in part, through the 
patterns observed from the detailed amino-acid sequence 
analysis of homogeneous myelorna immunoglobulins. The 
immunoglobulin molecule is comprised of two different 
polypeptides, light and heavy chains (4). All irnmunoglobulin 
chains can be divided into two segments, the variable (V) and 
the constant (C) regions, which code, respectively, for the 
antigen-binding and the various effector functions of the 
antibody molecule (5). There are three families of immuno-
globulin genes, which are unlinked in the mammalian genome .. 
Two code for light chains [lambda (>-.) and kappa (")] and the 
third codes for heavy chains (1). The V and C genes of a given 
family appear to be coded by separate germ line genes (6). 
::.\Iyeloma proteins from the inbred BALB/c mouse have 
proven to be a fruitful system for the analysis of amino acid 
sequence patterns because tumors can be induced at will and 
are readily transplanted from one individual to a second (7) . 
In addition, these inbred mice are presumably genetically 
homogeneous, in contradistinction to the genetic poly-
morphi5m prr.:;ent in most outbrecl populations such as 
humans and rabbits. · 
Abbreviations: V and C, variable and constant regions of irn-
m11noglobulin c·h:1in:;. 
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Two important patterns relevant to theories of antibody 
di\"er;;ity have emerged from the sequence studies on myeloma 
proteins. First, the V regions from most immunoglobulin 
families can differ so extensively that all immunologists agree 
that they are coded by multiple germ line l' genes. Thus, all 
theories of antibody diversity are rnultigenic, the question at 
i5sue is how multigenic. Second, when the V regions from large 
numbers of rnyeloma light or heavy chains ate compared, 
three to four sections of extreme sequence variability are 
noted, which are designated "hypervariable regions" (8, 9). 
X-ray crystallographic studies have established that antibody 
polypeptides fold so that hypervariable regions constitute the 
walls of the antigen-binding crevice (10, 11, 32). The presence 
of hypervariable regions that make up the antigen-binding 
site has divided somatic theories into two groups. Both agree 
that the total antibody di\·ersity is coded in part by germ line 
Y genes and in part by Y genes somatically derived from the 
germ line by mutation and stepwise selection for superior an-
tigen binding sites. One class of somatic theorie::i argues that 
the selection for somatic variants occurs predominantly, if not 
exclusi>·ely, in the hypervariable regions (2), whereas, a second 
group of somatic theories argues that somatic variation can 
occur throughout the entire V region (3). 
Previous studies from our laboratories have as;;essed the · 
clinrsity present in myeloma proteins from the two light chain 
families of the BALB/c mouse,>-. and,. (12-16). In this paper 
we extend these studies to include an analysis of the N-
terminal 20 amino-acid residues of 28 myeloma heavy chains 
clerind from BALB/c mice. These sequences lie outside the 
hyperrnriable regions of the heavy chain and will, accordingly, 
place different constraints on the various theories of antibody 
<li\·ersity outlined above. 
l\IETHODS AM> RESULTS 
:.\louse myeloma proteins were isolated from serum of tumor-
bearing BALB/c mice by immunoabsorption for those 
examples ;vith known specificities; J558 and l\IOPC lME on 
dextran B-13558-polyacrylamide gel (17), W3129 and 'Y3434 
on Sephaclex G-75, and S23 on dinitrophenyl (Dnp) Sepharose 
(lS). J606 and Y.5606 were precipitated from serum by dialysis 
again:::t 0.01 i\I XH1HCO. (19). Y5476, Y2020, Y5444, 
\\"30S:?, and Sl 76 were isolated by the methods described by 
Potter (20). The purified proteius were partially reduced and 
alkylated and hraYy and light chains were separated as 
described by Bridges aud Little (21). The heavy chains were 
de.::alted, lyophilized, and approximately 10 mg per run was 
lon.derl on the sequencer. 
Proc. Nat. Acad. Sci. USA 71 (1974) 
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Light 
Tumor Jg Cha.in Activ-
Number Class Type I s 10 15 20 ity 
Prototype V.ai EVQLQESGPSLVKPSQ TLSL 
M460 Jg A * Dnp 
" S23 lgA 
" 
Dnp 
M315~ lg A :>. D G-----S--- Dnp 
Prototype VII II EVQL QESGPEL VKPGASVKl\I 
J558 lg A :>. .. .. l,3D 
Ml04E lgM 
" 
l,3D 
Prototype Y1n II EVKL LESGGGL VQPGGSLKL 
Y5476 lgA L 
W3434 Jg A 
" 
l,6D 
W3129 lgA --vr• • 1,6D 
" Ml73° Jg A 
" 
P-L---- u 
H2020 lgA 
" 
-Q-V .. u 
Y5444 lgG2a >. -M-V .. u 
s1od lg A - l,6G 
x21d lgA * l,6G 
X44d lg A 
" 
l,6G 
TI9ld lg A 
" 
l,6G 
J539d JgA l,6G 
Jld lg A ---1------- l,6G 
Hs• JgA 
" 
--v R- PC 
Tl5° Jg A 
" 
--v R- PC 
s101• Jg A --v R- PC 
M603° lgA --v R- PC 
Ml67° lg A --vv R- PC 
YS606 lgG3 >. D-Q-V * z-- T.MA 
M21Ah lg A D-Q-V M- u 
M406b lgA 
" 
D-- .AI\-f 
W30B2 lg A 
" 
--E M- L 
J606 lgG3 --E M- L 
Prototype V:mv EVQLQZSGTVLARPGSSLKM 
8176 major lg A >. 5AU 
8176 minor lg A 
" 
5AU 
Fm. 1. N-terminal sequences of BALB/c heavy chains. 
Tpe one letter code of Dayhoff (28) is: A, Ala; B, Asx; C, Cys; D, 
Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; I\:, Lys; L, Leu; ?11, 
Met; N, Asn; P, Pro, Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, 
Trp, X, ?; Y, Tyr; Z, Glx; lg indicates immunoglobulin; 
Dnp designates dinitrophenyl; l,3D indicates a-1-+3 dextran; 
l,6D designates a-1--+6 dextran; U indicates unknown specificity; 
L designates levan; Al\1 designates N-acetyl-~-mannosamine; 
1,6G indicates {:l-1~6 galactan; PC indicates phosphorylcholine; 
Tl\JA designa.tes trimethylamine; and 5AU is 5-acetyluracil. 
• From reference 29. b Quoted in ref. 7 and represents sequences. 
derived from a single sequentor run (J. M. Kehoe andJ. D. Capra, 
personal communication).• From 30. d From 31. •From 24. *in-
dicates uncertainty about amide or residue assignment. l\ll04E 
indicates l\lOPC 104E; M406 indicates l\IOPC 406; the remainder 
of the complete names for the proteins is given in ref. 16. 
Each chain was subjected to 20 steps of automated Edman 
degradation on an updated Beckman 890.A. protein sequenator 
employing a standard Quaclrol or D.i\IBA program. Samples 
were dried under N2 and converted to the phenylthiohy-
dantoin amino acids (PTH) by treatment with 1 M HCl-1 
m~I ethanethiol for 10 min at 80°. Following extraction in 
ethylacetate, 5% of each sample was run on a Hewlett 
Packard gas chromatograph equipped with dual glass 7.5% 
DC-560 columns. Glutamine-glutamic acid and asparagine-
aspartic acid were resolved by thin-layer chromatography on 
silica gel (benzene: acetic acid, 9: 1) or by silylation of the 
phenylthiohydantoin derirntives followed by gas chromatog-
raphy. The amino acids were then regenerated by hydrolysis in 
hydriodic acid for 18 hr at 120° (22) and analyzed on a Dur-
rum D-500 amino-acid analyzer. Throughout these experi-
ments phenylthiohydantoin norleucinc was added to the 
sequencer tubes prior to conversion, to normalize for any 
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TABLE 1. Percent homolO{J1J between mouse and human 
prototype sequences for the N-terminal 20 residues 
*l\lVmr l\lV mrr MVmv *HVm HYnrr HY nm 
:'.\!Vm 65 45 55 40 65 45 
l\!V Ell 60 75 70 50 60 
:MVmu 60 45 50 85 
i\IVmv 55 40 60 
HVm 40 50 
HVnu 50 
* l\1Vm nnd HVm respectively denote the prototypes from 
mouse and human Vu regions. The human prototype sequences 
are derived from the data gi vert in ref. 26 . 
losses due to handling. The methodologies used have been 
described in detail in a previous publication (16). Yields of 
appro:-imately 50% of the theoretical values were noted at 
step 1 and repetitive yields averaged 903 for all chains. 
DISCUSSION 
Selection of Proteins. The heavy chains used in this analysis 
were generally selected because the irrununoglobulins from 
1>ruch they were derived exhibited specific binding for one or 
more haptens (Fig. 1). 
Patterns of Diversity. The amino terminal 20 residues. of 13 
heavy chains are compared with 15 sequences taken from the 
literature (Fig. 1). Sixteen of the 28 sequences differ by one 
residue or more. By sequence homology, these sequences can be divided into four major sets, which contain, respectively, 
22, 3, 2, and 1 proteins. Prototype sequences can be derived 
for each of these sets by selecting the major residue alternative 
expressed at each position (Fig. 1) and these are respectively 
designated prototypes V:mll, Vm, Yun, and Vmv.§ The four 
prototype sequences differ from one another by 25--55% of 
their residues (Table 1). Prototype set Vmn can be broken 
down into at least four subsets that are defined by two or more 
linked residues. For example, the heavy chains from W3082 
and J605 have a glutamic acid at position 5 and a methionine 
at position 18 that distinguish these proteins from the remain-
ing proteins of this set (Fig. 1). In this fashion, the heavy 
chains from HS, Tl5, S107, .i\1603, and l\1167 as well as Y5606 
and l\I21A can also be divided into two additional subsets by 
the presence of linked amino acids (Fig. 1). 
The variable region of the heavy chain (Vu region) is about 
120 residues in length and hence the N-terminal 20 residues 
represent about 1/6 of the Vn region. Accordingly, a rough 
I 
§The largest set of heavy chains is designated V.am because 
the chains show the greatest homology with the human heavy 
chains belonging to the Vnm subgroup (see ref. 26). We have 
refrained from using the term V region subgroup for two reasons. 
First, with the accumulation of large amounts of sequence data jt 
hus become apparent that the definition of what constitutes a 
subgroup is uncerta1n. For examp1e, with1n many subgroups, 
additional groupings are defined using smaller numbers of linked 
residues. Are these new groupin6-:; additional V region subgroups? 
Second, the term V region subgroup has had the genetic implica-
tion that it is encoded by at least one germ line gene. Yet el>Ch of 
the the0rie:; of antibody diver:;it.y incorporates very different 
ideas about what. types of sequence patterns define additional 
germ line l' genes. Thus we feel the term subgroup is undefirntble, 
has confusing genetic implications, and shou1d be repluced by a 
more neutral term such a,; "set .. " 
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FIG. 2. A genealogic tree of heavy chains from BALB/c myeloma proteins. This tree was constructed using only the N-terminnl 20 
residues. l\fany of the immunoglobnlins from which these VH regions were derived bind to one or more haptens. These specificities are 
shown below the tumor number. Abbreviations: Dnp, dinitrophenyl; PC, phosphorylcholine; l,6D, a-1-+-6 dextran; I,3D, a-1~3 clex-
tran; L, Levan; TMA, trimethylamine (7). 
estimate of the number of amino-acid differences between two 
Vu regions can be determined by multiplying the difference in 
diversity shown over the N-termi1ial 20 residues by six (this is 
an underestimate because no hypervariable regions are 
included in this region). Thus, proteins in different sets will 
probably differ by 48 residues or more, whereas proteins within 
a set can, from this estimate, differ by as many as 24 or more 
residues. The only two nearly complete mouse Vn sequences 
from different sets, l\1315 and Tl73, are consistent with the 
above analysis in that they differ by 10 residues in the first 20 
and by 62/104 residues and two sequence gaps. 
Theories of V Gene Diversity. A more sophisticated examina-
tion of these proteins can be carried out by a genealogic analy-
sis (1). The sequences within any set can be related to one 
another by an evolutionary tree which depicts the minimal 
number ·of genetic events (i.e., single base substitutions) 
required to generate this set of sequences from a single 
ancestral sequence (gene). This procedure permits a step by 
step analysis of the single base substitutions required to gen-
erate diversity in a given set of sequences. One can then ask 
what events are compatible only with germ line evolution and 
what events might be explained by somatic evolution. The 
genealogic analysis in Fig. 2 shows that the relationships of 
these sequences to one another are somewhat more complex at 
the nucleotide than at the protein level because certain single 
amino-acid differences are coded by two base substitutions. In 
spite of this, four distinct branches are noted on the gcnealogic 
tree, which correspond to the four sets of sequences described 
previously, Vm through Vmv. The Vrrr branch is divided into 
.five or more sub-branches by the presence of linked nucleotide 
bases in certain of the sequences (e.g., TlS-167-54-1<1; 3082-
606; 5476-3129-Jl; 2020-5GOG-.:\12IA~106; and 173-see Fig. 2). 
Obviously additional data will be required (more and longer 
sequences) to more sharply delineate this gcnealogic tree, 
particularly with regard to the sub-branch strueture of Vmrr. 
The somatic theory which urgnes for somatic variation only 
in hyperrnriable regions (2) and the germ line theory would 
agree on the conclu~iQns to be drawu from this genealogic tree; 
namely, each of the V regions that differ from one another is 
coded by distinct germ line V genes that arose by gene duplica-
tion, sequence divergence (mutation, recombination, etc.) and 
selection during the evolution of the species. Thns both of 
these theories would agree that the diversity noted in these Vu 
regions must be coded by at least 16 germ line l'11 genes. If, 
however, it is postulated that rephcements in the N-terminal 
20 residues result from somatic mutation and selection, two 
questions must be asked. First, how many single base substitu-
tions are reasonable to postulate during the somatic develop-
ment of a given lymphocyte line? Second, how many parallel 
(or identical) mutations may occur in lymphocyte lines in 
separate individuals? If somatic diversification occurs by 
ordinary random mutation followed by selection, then it 
would appear likely that relatively few (i.e., 1-5) mutations 
occur per lymphocyte line because of the need to select and 
expand out each mutant clone of lymphocytes (2). In addition, 
no selectiYe forces adequate to explain significant parallel 
mutation have been postubtecl to occur somaticaliy, thus each 
set of sequences with multiple linked residues is probably 
derived from a different germ line gene (2). _.\.ccordingly, from 
the viewpoint of random sornatic mutation that can occur 
throughout the entire V gene, at least eight germ line Vu genes 
must be postulated for this group of VH regions, one for each 
distinct branch and sub-branch of the genealogic tree. A dis-
cussion "of other somatic theorie.~ is beyond the scope of this 
·report. 
The mouse hea\·y chain sequences examined here appear to 
exhibit less di\·er;;ity than the mou;;e " fomi!y and far more 
diver;;ity than the mouse A family. This generalization <;houlcl 
be qualified, ho\re\·er, because most of the;;e Va sequences 
\\·ere derived from imrnunoglobulins selected because they 
exhibited bindin~ acfo·ity for various haptcns. Thus, these 
hea\·y chains certainly constitute a selected subset of R\.LB/c 
hca\·y chain myeloma pool. The degree of selection that 
occurred in examining primarily Vu regions dcri\·ed from 
rnycloma protein . ..; \1·ith binding acti\·ity is entirrly unknown. 
Proc. Nat. Acad. Sci. USA 71 (1.974) 
It will be very important to analyze the diversity exhibited by 
unselected Vn regions to obtain a more reliable estimate of the 
diversity present in the BAL13/c pool of myeloma hea\·y 
chains. In addition, mouse heavy chains blocked at their 
N-termini comprise about 783 of the normal serum immuno-
globulin (23). Thus it will b~ particularly Yaluable to analy?e 
the extent of diversity present in these blocked sequences. 
Normal Pooled Mouse Heavy Chains Appear to be Jfore 
Restricted in Sequence Than the Pool of Jlfyeloma Heaiy Chains. 
A recent study reports that normal pooled mouse heavy chaim 
differ in two respects from the sequences reported here. First, 
as mentioned earlier, the normal mouse H chains have a 
blocked a-amino group in 783 of the proteins (23). Only one 
of 20 myeloma H chains we examined was blocked (HOPC-1). 
Second, the pool of unblocked mouse H chains obtained from 
the serum appeared to have a single residue at the 953 level 
at most of the N-terminal 28 positions. This is in striking 
contrast to the myeloma data we have reported here. For 
example, in the pool of myeloma heavy chains, aspartic acid i;; 
seen in 143 of the sequences at position 1; glutamine is seen in 
323 of the sequences at position 3; the alternatives at position 
5 are e\•enly spread among a number of residues. Thus, the 
myeloma pool of heavy chains reveals a heterogeneity not 
detectable by sequencing the normal pool, because the my-
eloma population, not surprisingly, expands individual 
sequences that are normally represented infrequently or not at 
all in the serum pool. Hence one must be cautious about draw-
ing concl11sions concerning the nature and extent of V region 
diversity from studies on normal pooled sequences. 
· It appears that the myeloma immunoglobulins are them-
sekes highly selected in that 53 or more of them bind to a few 
determinants (7). This is unexpected in view of the enormous 
functional heterogeneity of the normal immune respon~e. 
Accordingly, both the normal and myeloma pools could be 
interpreted not to represent the true V region diversity that is 
coded in the 13:\LB/c genome. 
One obvious difference between the myeloma pool and the 
normal serum pool is the fact that the artificial induction of 
myeloma proteins in BALB/c mice selects primarily lg:\ 
proteins, whereas the normal serum pool is mostly of the IgG 
type (7). Obviously, an analysis has yet to be carried out of the 
extent and nature of amino-acid sequence diversity in the VH 
regions associated with BALB/c 'Y heavy chains. In any case, a 
critical question arises. Are the Vrr regions associated ·with C-y 
regions distinct from those associated with C., regions? If the 
VH regions from 'Y and a myeloma proteins are equally 
<lh-erse, then the normal and myeloma heavy chain pools 
express the same family of germ-line VH genes. If the "frr 
regions from 'Y myeloma proteins are less diverse than tho3e 
from their a counterparts, then selection nnist occur in the 
association of certain germ-line VH genes with given CH genes. 
Some ~llouse Vu Regions Are Similar lo Their Human 
Counterparts, ll"hereas Others Are Quite Distinct. A rough 
compari::;on o; the $imilarity of mouse and human hea\·y chain5 
at their I\-tcrmini can be made by comparing the prototype 
sequences of the mouse and human Yn sets (Table 1). The 
mbu:3e and human prototypes are quite distinct from one 
another (30-603) apart from the mouse and human Ymn 
sequences (about 153 difference) . The comparison of the 
;;ingle nearly complete human Ymrr sequence (Nie) with tl'·o 
mou.se Vn regions (.:.\Il73-39% and .:.\I315-G13) sugge::b thu.t 
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the group of mouse sequences to which. l\Il73 belongs is more 
closely related to the human Vmrr sequences than other 
mouse V H regions are, although they are not as closely related 
as suggested by the N-terminal data. The fact that many 
mouse VH prototypes are as closely related to one another as to 
their human counterparts suggests that multiple Vn genes 
existed in the mouse-human ancestor (Table 1). Thus some of 
the YH genes in human and mouse may have been derived 
from a common Y11 gene in the human-mouse ancestor, 
whereas others appear to have diverged from distinct genes in 
this ancestor. The heterogeneity of the myeloma heavy chains 
at the K-terminus compared with their normal counterparts 
also suggests that from the analysis of normal pooled se-
quences it is not possible to conclude that species- or phylo-
genetically associated residues are coded by a major portion of 
the germ-line V genes. 'If 
The Haplen Binding Properties of Certain Myeloma Proteins 
Appear lo Correlate with Their HeamJ Chain Sequences. Six 
groups of myeloma proteins with binding activity for different 
haptens are shown in Fig. 1. The binding activity for a specific 
hapten appears to correlate with the sequence of the N-
terminal 20 residues (Figs. 1 ancl 2). Indeed, each of the major 
branches on the genealogic tree with just a few sequences 
correlates with a single hapten binding activity (e.g., dinitro-
phenyl-Ym, a-1-+3 dextran-Vmr, and 5-acetyluracil-
Ymv). The binding specificities for heavy chains in the Vmn 
branch generally correspond to the linked sets of proteins or 
subbranches that occur within this branch (e.g., the phos-
phorylcholine and levan binding heavy chains). Other studies 
suggest that the correlation of specificity with distinct amino-
acid sequences is much greater with the heavy than with the 
light chain sequences (24). 
The Correlation of Particular Antigen Binding Specificities 
uith Particular N-Terrninal Sequences S11ggests That Selection 
for Function Occurs Outside As Well As Within Hypen·ariable 
Segments of V Regions. This observation renders unlikely 
theories of antibody diversity that argue that speeial hyper-
mutational mechanisms operate only in the hypervariable 
regions or that the hypervariable regions are coded by separate 
episome-like genes which are integrated into a framework Y 
gene. Clearly, mutation and selection occur through the entire · 
l' gene. The relative contributions of germ line versus somatic 
diversification to this process remain uncertain. · 
Heaiy Chains May Have a Precursor with Additional Resi-
dues at the N-Terminus. The amino-acid sequence analysis of 
Sl 76 revealed a mixture of two sequences, probably identical 
to one another but for a single extra residue at the N-terminus 
(Fig. 1). A recent report has demonstrated that a myeloma 
light chain synthesized in vitro has an additional 10-15 
residues o~ the N-terminus (2.5) which are, presumably, 
cleawd off by a post-translational event in vivo. Accordingly, 
we suggest that heavy chains also have a precursor form that is 
modified post-translationally. The presence of the normal 
heaYy chain in this tumor product suggeo;ts that the extra 
::\-terminal residue cannot be accounted for by a mutational 
ewnt at the DNA level. 
-; :3pe<·ies- or phylogenetirally a%ociated residues arc those found 
at a particular position in most of the serum irnmunoglobnlin 
chain,; of one species and which are dist inct from the homologons 
re:-;idnes of a second species (23, 27). 
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Are There An!} Differences in the Set of VH Regions Asso-
ciated with A. As Compared to k Light Chains? None of the 
heavy chains associated with A. chains has a lysine at position 
3, a residue found in the heavy chains associated with 18 of 21 
"type molecules (Fig. 1) . Eight of nine heavy chains derived 
from X type molecules have glutamine at position 3. On the 
other hand, the Vn regions from 1\1315 and i\I,!60 as well as 
Y5606 and M21A are quite similar, yet in each case one mole-
cule is of the X ancl the other of the "type. Obviously a great 
deal more sequence data must be available before conclusions 
can be drawn regarding Vu associations '>'lith V x and V K 
regions. 
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Additional Data 
We have determined the heavy chain variable region sequences 
from two molecules which bind phosphorylcholine, H8 and Sl07. 
In collaboration with Rudikoff, we have also determined the 
variable region of the Tl5 heavy chain. In addition, we have 
determined the N-terminal sequences from M511 and W3207. These 
studies reveal that the heavy chains from PC-binding myeloma 
proteins represent multiple variable region genes. Two iden-
tical heavy chain variable regions, Sl07 and Tl5, occur within 
molecules with the Tl5 idiotype. A third molecule with this 
idiotype H8 has a single amino acid difference from Tl5, how-
ever. This difference indicates that serologic identity may 
not imply variable region sequence identity. The high degree 
of sequence homology observed within these total heavy chain 
variable regions supports the concept of heavy chain sequence 
importance in determining the hapten-binding activity of the 
intact molecule. 
Materials and Methods 
H8 and Tl5 tumors were obtained from Dr. s. Rudikoff, 
NIH, Bethesda, Maryland. Tumors W3207, Sl07 and M511 were 
obtained from the Salk Institute, San Diego, California. 
All solid tumors were converted to ascites form by passage 
through an 80 mesh screen and injection intraperitoneally 
into (DBA/BALB) F1 mice. Ascites fluid was collected after 
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three weeks by paracentesis with an 18 gauge needle. Each 
paracentesis yielded from 5 to 15 ml of fluid. 
Purification of Irrununoglobulins. Phosphorylcholine speci-
fic immunoglobulin from each tumor was purified by affinity 
chromatography according to Chesebro and Metzger (26). 
Chain Separation. Heavy and light chains were separated 
according to (27) on an upward flow 5 x 150 cm G-150 column 
in 5 M GuHCl buffer in .2 N NH4Hco3 • 
Preparation of Cyanogen Bromide Fragments. The generation 
and isolation of cyanogen bromide fragments as outlined in 
Fig. 3 was done according to Rudikoff and Potter (27) with the 
following changes: Fragment CN2 was generated from intact 
heavy chain. The CN2 was desalted on a Biogel P-2 column 
(6 x 50 cm) in 5% formic acid. The precipitation of CN2P 
(residues 85-165) was carried out by dissolving CN2 in .01 N 
acetic acid and changing the pH to 9.5 by the addition of 
1 N NH40H. This procedure gave a better yield of CN2P in our 
hands than the technique previously published. 
Sequence Analysis. Approximately one micromole of each 
peptide was subjected to 36 or 45 cycles of automated Edman 
degradation on an updated Beckman 890 A protein/peptide 
sequenator using the DMBA program of Hermodson et al (22). 
Each residue was analyzed as in {20). 
Trypsin Digest of CN2P. Approximately 150 nm of CN2P 
was dissolved in 200 µl of .01 N acetic acid. Two nm trypsin 
(Calbiochem grade B) was added in 20 µl 10-3 N HCl. Two hundred 
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Fig. 3.--Protocol for isolation of variable region cyanogen 
bromide peptides of heavy chains from H8, Tl5, and Sl07. Num-
bers over line indicate methionine locations. For details, 
see text. Fragments of interest in this paper are CNlC (residues 
85-165), CNlD (residues 1-34) and CN2P (residues 35-84). The 
supernatant fraction from CN2 contains two or more constant 
region peptides, CNlA is a large constant region peptide be-
ginning at position 166 and CNlB appears to be a complex mix-
ture of peptides generated in low yield. 
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µl of .2 N NH4Hco3 was added to start the digest and caused 
most of the CN2P to precipitate. The digest was incubated 
for one hour at 37°c with frequent vortexing. An additional 
2 nm trypsin was then added and the vortexing and incubation 
were continued for one more hour after which the solution was 
frozen and lyophilized. 
Peptide Maps of CN2P. The lyophilized digest was dissolved 
in .1 N acetic acid and 1/3 was placed on the analytical map 
and 2/3 on the preparatory map. Descending chromatography 
was performed in water saturated butanol:acetic acid (540:160) 
for 18 hours on 46 x 57 cm Whatman 3 mm chromatography paper. 
After drying at 80°c for 15 minutes, electrophoresis was run 
at pH 3.5 in pyridine:acetic acid:water (1:10:290) for one 
hour at 3000 V. After drying again the analytical map was 
dipped in a collidine-ninhydrin solution consisting of 1 g 
of ninhydrin in ethanol:acetic acid:collidine (600 ml:200 ml: 
80 ml)~ Peptides were visible after 15 minutes at so0 c and 
were cut out, eluted in 1 N NH40H, dried under nitrogen, 
and hydrolyzed for 15 minutes at 160°c in 12 N HCl propi-
onic acid (1:1) (28). The NH40H reacts with excess ninhydrin 
making it possible to obtain peptide compositional data from 
an analytical map {E. Loh, unpublished observation). Following 
hydrolysis, the composition of each peptide was determined by 
electrophoresis for two hours at pH 1.7 (29). 
Preparative maps were sprayed with 1% ninhydrin in acetone 
(Pierce Chemical Co.) and the peptides were cut out and eluted 
62 
in 1 NH 40H as soon as they became visible. Hydrolysis on the 
peptides of interest was done at ll0°c in 6 N HCl for 24 hours. 
The amino acid compositions for these peptides were determined 
on a Durrum D-500 amino acid analyzer using a 72-minute program. 
Results and Discussion 
The amino acid sequences for the entire heavy chain vari-
able regions of four myeloma proteins which bind PC are shown 
in Fig. 4 along with portions of two others. These variable 
regions are highly similar in sequence. This 90% or greater 
sequence homology within this set of heavy chains correlates 
with the concept that the heavy chain structure is important 
in determining the hapten~binding specificity of the molecule. 
The N-terminal 20 residue sequences for the heavy chains 
W3207 and M511 are identical to Tl5. The Tl5 branch on the 
genealogical tree now represents six proteins, all of which 
were derived from tumors which bind PC. 
Molecules which are serologically identical can differ 
in their amino acid sequence. Three of the heavy chains in 
Fig. 4, 8107, Tl5, and H8, are from parent molecules which 
all have the TlS idiotype, (15) i.e., they are serologically 
indistinguishable. Two of these heavy chains, Sl07 and TlS, 
are identical for their entire variable region amino acid 
sequences. As indicated in Fig. 5, however, sequence analysis 
· shows that H8 differs from Tl5 and Sl07 at position 105. These 
data were obtained following purification and automated sequence 
analysis on peptides CNlC (residues 85-165) from all three 
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Fig. 4.~~The total heavy chain variable region sequences 
from four BALB/c phosphorylcholine-binding myeloma proteins. 
W3207, M511, 8107, and H8 are from this thesis. Tl5 was se-
quenced in collaboration with Rudikoff. M603 is from (27). 
Horizontal lines indicate homology with Tl5. Letters indicate 
the appropriate amino acid using the single letter amino acid 
code: A, alanine: B, aspartic acid or asparagine; C, cysteine; 
D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; 
H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; 
N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; 
T, threonine; V, valine; W, tryptophan; Y, tyrosine; and Z, 
glutamine or glutamic acid. { } denotes a gap. ( ) indicates 
sequence by peptide composition homology only. 
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Fig. 5.--Mole percent data from the Durrum D~500 analyzer 
of steps 20, 21, and 22 from CNlC of Tl5, H8, and Sl07. The 
residue indicated by gas chromatography is shown on the line 
marked G.C. In HI hydrolysis PTH-serine is converted to ala-
nine in approximately 50% yield (25) . Prior to hydrolysis 
of the PTH's back to amino acids, the asx was resolved to be 
asn by thin-layer chromatography (24). The major residue 
at each position is underlined. 
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heavy chains. Cl~arly position 21 in H8 CNlC (residue 105) 
is an asparagine in contrast to the serine found at this 
position in both Tl5 and 8107. Each sample was sequenced 
twice to verify this finding. 
The observation of a single amino acid substitution with-
in molecules with the Tl5 idiotype indicates that the anti-
idiotypic antisera is not absolutely specific. It did not 
detect the single heavy chain variable region difference and 
thus genetic implications drawn from serological studies 
must be made cautiously. In view of the fact that the light 
chains from Tl5 and H8 appear to be identical for the first 93 
residues . (this thesis) the intact immunoglobulins are extremely 
similar in structure and it is not surprising that serologi-
cally they are indistinguishable. 
The genetic mechanism responsible for the H8 difference 
could be one of three alternatives. Since the TlS and 8107 
heavy chain variable region sequences are identical, they 
appear to be encoded in the BALB/c germ line DNA. Three alter-
native mechanisms could explain the single base substitution 
which would generate the H8 sequence: (1) H8 could represent 
a second germ line gene generated by a gene duplication of the 
Tl5 gene which has subsequently accepted a single base substi-
tution, or (2) it could reflect a polymorphism of the Tl5 heavy 
chain gene which exists in a subset of the BALB/c mice, or 
(3) it could have been generated by mutation in the soma of 
a Tl5-producing cell which was subsequently transformed. H8 
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does not have a higher binding affinity (15} for PC than Tl5, 
thus this mutation does not appear to have a selective advan-
tage, and therefore, it does not appear to be a case of antigen-
driven somatic mutation ( 9 ). Further sequence analysis of 
other heavy chains from molecules with the Tl5 idiotype will 
determine if the H8 sequence is found again. If this sequence 
recurs, the third explanation .would appear unlikely. 
The PC-binding m:yeloma proteins must represent four germ 
line VH genes. Since Sl07 a nd Tl5 have identical VH regions 
and H8 differs by only a single base mutation, any somatic 
mutational mechanism responsible for additional diversity 
which might exist must operate at a very low level (if at all) 
in these cases. Ml67 (30), MSll (31), and M603 all differ 
from one another as well as from Tl5 by multiple amino acid 
substitutions and insertions or deletions (Fig. 6). If these 
sequences were all generated from the Tl5 germ line gene, the 
mechanism responsible for generating these differences must 
be very complicated. First of all it must be capable of opera-
ting at different rates in different cells since the Tl5 -
Sl07 sequences are identical while Ml67 differs by ten sub-
stitutions and three size differences. Do different rates of 
mutation represent different enzymes or cofactors? Second, 
the mechanism also must operate in the framework as well as 
the hypervariable regions since the differences are located 
in both areas. Third, it must be able to break DNA at any of 
three different points in the variable region, insert codons 
69 
Fig. 6.--Comparison of the amino acid sequences and 
lengths of the variable regions from the heavy chains of 
phosphorylcholine-binding myelorna proteins. The line 
marked substitutions indicates the number of amino acid 
differences from TlS. The line marked length compares 
the length of each VH with that of TlS, thus M603 is one 
residue shorter than TlS, while M511 is one residue longer. 
M511 is from (31) and Ml67 from (30). 
Substitutions 
Length 
Sl07 
0 
0 
H8 
1 
0 
70 
. M603 
4 
-1 
M511 
3 
+l 
Ml67 
10 
+3 
71 
and splice the DNA back together in phase each time such that 
a functional molecule will be produced. Such a mechanism 
would be extremely complex and appears unlikely. It seems 
more reasonable to believe that Tl5, Ml67, M511, and M603 
represent four different germ line VH genes. 
The N-terminal differences between V regions from normal 
antibodies and myeloma proteins must be due to the antigenic 
environments involved. A recent report (32) indicated that 
human IgA heavy chains are 67% unblocked compared to 25% for 
those from IgG. While this class difference in VH expression 
is suggestive, it does not explain the large percentage of 
unblocked VH regions found in our study of -myeloma proteins. 
Our study contained three IgG molecules and all three are un-
blocked. Since each VH from a mouse IgG molecule has only a 
.22 probability of being unblocked if the IgG myelomas and IgG 
normal antibodies express the same VH regions, the probability 
of finding all three IgGs unblocked in our study would be 
(.22) 3 or about 1 in 100. · Thus, the classes of the immuno-
globulins involved does appear to adequately explain the dif-
ference in the fraction of unblocked heavy chains observed in 
the two studies. 
A more reasonable explanation of this difference is that 
the antigens expressed in the gut and circulation differ and 
since the hapten-binding activity of the molecule correlates 
with the VH N-terminal sequences, the VH sequences observed 
should also differ. Heavy chains expressed in specificities 
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for gut flora may be predominantly unblocked while those spe-
cific for circulating antigens are mostly blocked. 
A recent finding by Capra (13) supports this concept that 
the VH sequence profile reflects the antigenic history of 
the organism. He reported that · the normal IgG response to 
p-azophenylarsonate has unblocked VH regions in the BALB/c 
mouse. Furthermore, these heavy chains are identical in se-
quence to our myeloma MVHII subset for the first 20 residues. 
This sequence, which differs by 40% from the single sequence 
reported at the 95% level or greater, was undetected in the origi-
nal study on unirnmunized animals (33). Upon reexamination of 
the original data, this MVHII sequence has been detected at 
the 5% level or less. This illustrates that sequence studies 
on pooled antibodies detect only a few major sequences at best 
and upper limits for total subunit diversity based upon these 
studies are of questionable value. 
The N-terminal 20 residues appear to be the most highly 
conserved block in the entire V region. Four nearly total 
BALB/c myeloma VH regions are compared in Table 2. The percent 
of sequence homology between each pair of V regions is indicated 
for the N-terminal 20 residues and the total variable region. 
For the purpose of this comparison, a deletion is counted as 
a single difference for each amino acid missing. In every com-
parison, the observed homology is greater for the N-terminal 
20 residues than for• the total variable regions. In examining 
all the total BALB/c VH regions sequences to date, the N-terminal 
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Table 2.--Percent homology between four BALB/c heavy chain 
variable regions. The number above the line indicates the per-
cent homology between the two VH regions in the first 20 resi-
dues. The number below the line indicates total VH homology. 
Total VH homol~gy is calculated from 116 residues for all chains 
except for Tl73 which employed only 104 residues. M21 is from (34), 
315 is from ( 35) , Tl 7 3 is from ( 36) , and Tl5 is from this 
thesis in collaboration with S. Rudikoff. 
Tl5 
M315 
Tl73 
M315 
60 
41 
74 
TABLE 2 
Tl73 
80 
55 
50 
40 
M21 
80 
59 
70 
41 
70 
63 
75 
section is the most highly conserved 20 residue block in 
the entire variable region. 
The heavy chain diversity must be analogous to that of 
the kappa chains. This N-terminal study e xamined the most 
highly conserved portion of a selected subset of heavy chain 
variable regions and yet considerable diversity in the VH 
regions is evident . The sequence variation observed in the 
total BALB/c VH regions appears comparable to that present 
in the BALB/c kappa chains . The BALB/c mouse thus appears 
to have two very diverse V region families available for the 
generation of antibody specificities. By combining various 
VH and VL regions to form different hapten-binding specifici-
ties, an organism could generate vast antibody diversity from 
a few thousand V region genes. 
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CHAPTER V 
The N-Terminal Diversity of 
Myeloma Proteins Which Bind Phosphorylcholine 
The publication in this chapter is from Science and 
is reproduced with the permission of the publisher. 
r,eprinted from 
iiJiarch 1974, Volume 183, pp. 962-964 
llmmunoglobulin Structure: Amino Tenninal Sequences o~ 
f\/louse Myeloma Proteins That ·Bind Phosphorylcholine 
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Immunoglobnlin Structure: Amino Terminal Sequences of 
Mouse Myeloma Proteins That Bind Phosphorylcholine 
Abstract. The amino terminal sequences of five light and heavy immunoglob-
ulin chains from myeloma proteins of the BALBI c mouse with binding activity 
to phosphorylcholine are presented. Except for a single substitution in position 4, 
all five heavy chains have identical amino terminal sequences through the first 
hypervariable region. Proteins which share unique (idiotypic) antigenic determi-
nants are identical through the first hypervariable region of their light and heavy 
chains. Proteins with differing idiotypic determinants have light chains of differing 
amino acid sequence. These observations suggest that the heavy chain plays a 
more important role than the light chain in determining the phosphorylcholine 
binding site. 
For the past several years, myeloma 
immunoglobulins produced by plasma-
cytornas in the BALBI c mouse have 
been screened against a limited series 
of antigens (1). Approximately 5 per-
cent of these proteins have been shown 
to exhibit specific binding activity. In 
many instances it has been possible to 
assign this binding activity to chemi-
cally defined haptens. Indeed, groups 
of proteins have emerged which bind 
the same haptenic determinant, for 
Chain Residue 
5 10 15 20 25 31 32 
abcdet' 
H8 D-I-V-M-T-E-S-P-T-F-L-A-Y-T-A-S-K-K-V-T-l-S-C.-T-A-S-Z...S-L-Y-S-S-K-l:l-K-V-R-Y-L-A-W 
Tl5 
Sl07 
M603 ------s-s-s-S-G-B-R--M--K-S---L-B-C-B-Z-K-B-F--
m67+ --I-Q-B-F~L-S-D-P--S-G-.E-S-S-T-
Fig. 1. The amino terminal sequences of K chains from myeloma proteins with bind-
ing activity to phosphorylcholine. HV1 indicates the extent of the first hypervariable 
region; HS indicates HOPC 8; T15 indicates TEPC 15; M603 indicates MOPC 603; 
and M167 indicates MOPC 167 [see (14)]. The one-letter amino acid code is: glycine, 
G; alanine, A; valine, V; leucine, L; isoleucine, I; serine, S; threonine, T; proline, P; 
cysteine, C; methionine, M; histidine, H; lysine, K; arginine, R; aspartic acid, D; glu-
tamic acid, E; asparagine, N; glutamine, Q; aspartic acid or asparagine, B; glutamine 
or glutarnic acid, Z; tyrosine, Y; phenylalanine, F; tryptophan, W. The numbering of 
residues for these chains is that taken from a homologous mouse " chain, MOPC 41 
(19). 
example, dinitrophenol (2), phospho-
rylcholioe (3-5), a-(I-; 3)dextran (6), 
{3-(I--; 6)-D-galactan (7), a-(1 --; 6)dex-
tran (8), /3-(2--; l)fructosan (8), and 
{3-(2~ 6) fructosan ( 8). Studies of the 
primary structure of proteins that bind 
the same hapten will be useful for de-
lineating structure·function relationships 
as well as providing possible insights 
into the genetic mechanism of antibody 
diversity. 
Che.in 
H3 
Tl5 
5107 
H70 
Tl24 
P.es !.c!ue 
30 31 32 
e.bc d er 
Z-S-L-Y-S-S-!C-!-!-!-~1-?.'-Y-L-:.-. ., 
---L-B----C-3-!-K-3-?-
--\'-3-~-!""I--~( ]-F-X-:--
r,:__:__;r-B-'!'-Y-C-3-~-[ )-F-~-4-
-V-3-'1-Y-G-3-S-( ]-?~ 
Refert' :":.Ce 
19 
20 
21 
This may rel:lect a common structural 
requirement for phosphorylcholine-
binding L chains. 
In this study we compare the partial• !·!63 
amino acid sequences of light (L) and -V-!l--Y-G-3-S-[ ]-?-~ 
-ll-I-C--L-( J-S-::--
21 
19 
The partial amino acid sequences for 
H chains from phosphorylcholine-
binding immunoglobulins H8, T15, 
Sl07, M603, and Ml67 are given in 
Fig. 3. The amino terminal sequences 
from these H chains are identical, apart 
from a single base substitution, leucine 
to valine, at position 4 in MI67. Heavy 
chains also have hypervariable regions 
whose properties are similar to those 
described for L chains. The first hyper-
variable region of H chains appears to 
extend from positions 27 to 35 as indi-
cated in Fig. 3. Perhaps the most strik-
ing finding in this study is the identity 
of all five H chains in the first hyper-
variable region, even though they were 
derived proteins with three different 
idiotypes. This observation assumes 
added importance in that the hyper-
variable regions appear to be in or 
near the antigen combining site as 
judged by affinity label and x-ray crys-
tallographic studies (I 5). Thus these 
regions may play a particularly critical 
role in ·determining the three-dimen-
sional configuration of the combining 
site. Indeed, the H chain sequence 
characteristic of the phosphorylcholine-
binding mye1omas has not been seen 
in any of the 23 other BALBI c V n 
sequences that were derived from im-
munoglobulins lacking this activity 
analyzed to date (16). 
heavy (H) chains from five BALBI c 
myeloma proteins that bind phospboryl-
choline. Previous studies have indicated 
that three of the five phosphorylcholine-
binding proteins, HS, T15, and S107, 
bind identical groups of related anti-
gens (9). The other two proteins, 
M603 and Ml67, bind groups of re-
lated antigens which distinguish them 
from each other and from those of the 
first group. In addition, immunologic 
studies have demonstrated that H8, 
T15, and Sl07 possess the same indi-
vidual antigenic specificity (idiotype) 
suggesting a high degree of structural 
identity (5). [These proteins are mem-
bers of the S63-TI5 idiotypic group 
(10) .] In contrast, the other two pro-
teins, M603 and M167, have unique 
antigenic determinants, which differen-
tiate them from each other and from 
the group with the shared idiotype 
(5). We were interested in examining 
the variable regions of the light (V d 
and heavy (Vn) chains from these 
proteins in order to determine how 
their amino acid sequences correlated 
with the antigen binding and idiotypic 
properties. 
The amino acid sequence analyses of 
partially reduced and alkylated im-
munoglobulin chains were carried out 
on a Beckman model 890A or 890C 
sequencer with the use of standard 
buffers. The phenylthiohydantoin amino 
acid derivatives were analyzed by gas 
chromatography, by thin-layer chro-
matography, and by amino acid anal-
ysis after hydrolysis of the derivatives 
to free amino acids (1 J). At least two 
sequenator runs were carried out on 
each polypeptide chain. 
The partial amino acid sequences for 
L chains from phosphorylcholine-
binding immunoglobulins HS, Tl5, 
SI07, Ml67, and M603 are given in 
Fig. I. Each of these L chains is of 
the kappa (K) type. Several important 
points can be derived from an analysis 
of these L chain data. It should be 
noted that L chains have three regions, 
residues 2S to 34, 50 to 56, and 90 to 
M21 -11-V-V-T-Y-( 22 
Tl73 1-- li~published 
Fig. 2. The first hypervariable region from 
myeloma K chains of the BALBlc mouse. 
The asterisk indicates the data presented 
in this report. 
97, which are far more variable than 
the remainder of the V region (12). 
These are termed hypervariable regions. 
Indeed, these regions are so variable 
that two randomly chosen myeloma L 
chains, from man or mouse, have a 
very low probability of showing iden-
tity in any one of the hypervariable 
regions (13) . Thus it is striking that 
the L chains from the three proteins 
demonstrating idiotypic identity, H8, 
TIS, and SI07, are identical for their 
first 41 residues which include the first 
hypervariable region (Figs. 1 and 2). 
The M603 L chain differs from the 
HS group by 18 out of 41 residues, 8 
of which are in the first hypervariable 
region. The M 167 L chain differs from 
tbe HS group at 14 out of the first 23 
residues, none of which are in the first 
hypervariable region (14). Thus at 
least three L chain sequences are pres-
ent among the five immunoglobulins 
with phosphorylcholine-binding activity. 
The first hypervariable region of the 
four L chains examined is two residues 
longer than that of any of the mouse 
K chains previously reported (Fig. 2) . 
C'nain 
5 10 15 
This is, to our knowledge, the first 
report in which hypervariable regions 
from both the L and H chains of inde-
pendently arising immunoglobulins with 
idiotypic identity have been shown, 
respectively, to be identical. Thus the 
results of this partial amino acid se-
quence analysis and some other studies 
on the remainder of the V regions are 
consistent with the supposition that 
immunoglobulins with identical idio-
typic specificities are identical in the 
Residue 
20 25 30 35 
H8 E-V-K-L-V-E-S-G-C-C-L-V-Q-P-G-G-S-L-R-L-S-C-A-T-S-G-F-T-F-S-B-F-Y-M-E-W 
Tl5 
5107 
M603 
m61 
Fig. 3. The amino terminal sequences of H chains from myeloma proteins with binding 
activity to phosphorylcboline. HV, indicates the span of the first hypervariable region. 
V region sequences of tht:ir L and H 
chains. 
If identical idiotypic specificities in-
dicate structural identity, then there 
are two indications that immunoglobu-
lins of the S63 idiotype are present in 
normal BALBI c mice. First, immuni-
zation of normal BALBI c mice against 
the phosphorylcholine determinant 
yields immunocytes producing specific 
antibody that can be inhibited in the 
Jerne plaque assay by idiotypic anti-
serum of the S63 type (17). Second, 
immunoglobulins of the S63 idiotype 
are found in the normal serum of 
BALBlc mice (Ila). These results 
suggest that the myeloma proteins with 
phosphorylcholine-binding activity are 
indeed an excellent model .system for 
studying the relation between structure 
and function in bona fide antibody 
molecules. 
Since the H chains, even from those 
proteins with differing idiotypic speci-
ficity, are identical for 36 residues, ex-
cept for a single amino acid substitu-
tion, it will be particularly interesting 
to determine whether the entire H 
chains from proteins of differing 
idiotypic specificity are identical 
(for example, T15 .· and M603). If 
so, perhaps this H chain sequence, or 
one very closely related. to it, is a pre-
requisite for all immunoglobulins with 
phosphorylcholine-binding activity. It 
has been shown that all myeloma pro-
teins with a-(1-> 3)dextrao activity 
have an identical lambda L chain (18). 
Proteins with {3-(1 -> 6 )-n-galactan 
binding activity have very similar se-
quences in both L and H chains (7). · · 
Thus in some instances either L or H 
chain may. play a d.ominant role in 
hapten binding, while in others 
a specific L and H pair may be rigidly 
required .. 
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If immunoglobulins of the S63 idio-
type are identical, this suggests that the 
corresponding V L and V n regions are 
coded by genes in the germ line of the 
BALBI c mouse, for it is unlikely that 
a random wmatic recombination or 
somatic mutation process would gener-
ate multiple identical antibodies in dif-
ferent individuals. In this regard, it 
will be interesting to determine whether 
the H chain from M 167 is identical 
to the others apart from a single sub-
stitution outside the hypervariable re-
gion, or whether other differences will 
be found. If a single substitution is 
present, it could be explained by a 
single base substitution, either in the 
germ line or' in the soma. 
The complete analysis of these pro-
teins as welt as those from groups with 
binding activity to other haptens should 
continue to provide insights into the 
structure, genetics, regulation, and evo-
lution of immunoglobulin molecules. 
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Additional Data 
We have determined the amino acid sequences of the N-
terminal regions of the light and heavy chains from two addi-
tional BALB/c phosphorylcholine (PC) binding myeloma proteins, 
W3207 and M511. In addition, we have extended the sequences 
of the H8 and Tl5 light chains to position 94. The N-terminal 
heavy chain sequences for both W3207 and M511 are identical 
to Tl5 through the first hypervariable region. W3207 light 
chain is highly similar to M603 light chain and M511 light 
chain closely resembles Ml67. The present data suggest that 
three subspecificities exist within the PC-binding myeloma pro-
teins. These specificities have highly similar heavy chain se-
quences but vastly different light chains. 
Methods and Materials 
Sequence analysis was performed as in using the DMBA 
program of Hermodson et al. (22). 
Preparation of Tl5L trypsin fragments. Fifty mg of Tl5 
light chain was succinylated according to (37). The light 
chain was then fully reduced and alkylated according to (27). 
Trypsin digestion and gel filtration were similar to that of 
Svasti et al. ( (38) with the exception that a G-100 column 
(2.5 x 150 cm) in lN NH 40H was used. The first major peak 
contained two fragments in about equimolar concentration and 
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these were sequenced as a mixture. Since one of the fragments 
was from the constant region (positions 109 to 155) it was 
possible to deduce the second sequence by subtracting the 
known residue at each step. 
Preparation of HB light chain tryptic fragments. Approxi-
mately 100 mg of HB light chain was fully reduced and alky-
lated (27). After this treatment, the light chain was margin-
ally soluble in the buffer used for the trypsin digest. Di-
gestion was carried out in 5 ml .2N NH4Hco3 using two 1% aliquots 
of trypsin (Calbiochem grade B) added at one-hour intervals. 
After two hours, the digestion was centrifuged and the super-
natant removed. The pellet was resuspended in .lN acetic acid 
and centrifuged again. The acetic acid supernatant fraction 
was brought to pH 9.5 with .lN NH 40H at which time the desired 
peptide precipitated from solution along with the N-terminal 
fragment. The precipitate was sequenced as a mixture of three 
components. 
Results and Discussion 
The heavy chain sequences for W3207 and M511 are identical 
to Tl5 for the first 35 residues. The e x treme sequence cor-
relation observed with the heavy chains from the first five PC-
binding proteins applies to W3207 and MSll. This is in agreement 
with the concept that the heavy chain sequence conservation 
is critical for the irnmunoglobulins which bind PC. Subsequent 
work reported in this thesis has shown that five of these heavy 
chains are unique in sequence, however. Thus, these heavy chains 
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represent a set of closely related molecules rather than 
the repeated expression of one variable region gene. 
The light chains from the PC specificity now fall into 
one of three subsets. The partial amino acid sequences for the 
seven light chains from the PC-binding inununoglobulins are shown 
in Fig. 4·. Three subsets can be delineated based upon their 
am~no acid sequence similarity. The first subset contains 
molecules which have the Tl5 idiotype and these light chains 
are identical in sequence in the areas examined. A second sub-
set contains light chains from two idiotypically distinct mole-
cules, M511 and Ml67. These two light chains differ from each 
other by only two residues in the first 23, yet are vastly dif-
ferent from any of the other light chains in this study. A 
third subset contains M603 and W3207 light chains. These light 
chains differ at only a single position in the first 29 resi-
dues, but again differ greatly from the other of the seven 
light chains examined. Each of these subsets must represent 
at least one unique germ line gene, thus three germ line VL 
genes must be expressed within the PC-binding BALB/c inununo-
globulins. 
Why do three light chain subsets exist? One explanation 
is that each subset represents inununoglobulins which bind to 
different natural antigens. Studies on the intact inununoglobu-
lins indicate that they do indeed differ in their relative 
affinities for both synthetic (39) and bacterial (15) struc-
tures, although the binding to PC itself appears to be relatively 
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Fig. 4.--N-terminal sequences of seven light chains from 
molecules which bind phosphorylcholine. The prototype sequence 
was generated by taking the most common residue in all BALB/c 
kappa chain sequences available at each position. Lines 
indicate sequence identity with the prototype and letters 
indicate differences using the single letter amino acid code. 
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equal for most of the molecules (40). The PC-binding immuno-
globulins may then represent molecules which bind to at least 
three different natural antigens, but which are all capable 
of reacting with phosphorylcholine. 
Two light chains from molecules with the Tl5 idiotype are 
identical for the first 80% of their variable regions. Prelim-
inary sequences for the first 93 residues of Tl5 and H8 light 
chains are shown in Fig. 5. The sequence.for H8L could be 
determined since the mixture consisted of the N-terminal frag-
ment plus peptides which began at 61 and 68. The sequence 
for the peptide beginning at position 68 could be confirmed 
by detection of the same residue seven steps later. Work is 
currently underway to separate these three fragments by gel 
filtration. In this case, light chains that are identical 
for the first 40 residues are identical for the majority of 
their variable regions. These two chains may represent 
repeated expression of the same V region gene. Since mole-
cules with the Tl5 idiotype have been found seven times within 
the BALB/c myeloma proteins, a much higher frequency than any 
other known idiotype, the myeloma system appears to selectively 
express certain V gene products. This selective expression 
is probably a result of clonal expansion due to antigenic 
stimulation prior to transformation since molecules with the 
Tl5· idiotype can be found in the circulation of unimmunized 
BALB/c mice (41). In view of this unequal frequency of ex-
pression, the value of calculations concerning the amount of 
diversity present within the V gene libraries based on random 
expression of V genes is questionable. 
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Fig. 5.--The amino acid sequences of the first 93 
residues from Tl5L and H8L. o 7 indicates data from a 
sequenator run; ( ) indicate sequencer results of residues 
which are uncertain; t indicates the composition of 
a peptide isolated from a fully succinylated trypsin digest 
(STD) of Tl5L as determined on the Durrum analyzer. Letters 
in the sequence represent amino acids according to the 
single letter code. 
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CHAPTER VI 
Immunoglobulins with Hapten-Binding Activity: 
Structure-Function Correlations 
This chapter is being submitted to Science for 
publication. 
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Abstract. The N-terminal amino acid sequences of light 
and heavy chains from immunoglobulins binding a variety of sim-
ple haptens are compared with available sequences from the 
literature. These comparisons suggest that 1) the heavy chain 
sequences correlate closely with hapten-binding specificity 
and 2) light chain sequences correlate closely with some spec-
ificities (i.e., carbohydrate moieties) but not with others 
(phosphorylcholine or dinitrophenyl {Dnp}). The following 
rationale is offered to explain these differing light chain 
results. Carbohydrate moieties ranging in size from trimers 
to hexamers must generally react with immunoglobulins through 
precise interactions involving hydrogen bonding of hydroxyl 
groups and van der Waals forces. Accordingly, the molecular 
complementarity must be precise, allowing little opportunity 
for light (or heavy) chain variation. In contrast, the Dnp 
and phosphorylcholine moieties are small and have many possi-
bilities for ionic or charge transfer interactions, presumably 
with a variety of groups in the large active site crevice. 
Hence a variety of light chain sequences are compatible with 
active sites that bind these haptens. However, the light chains 
from myeloma proteins binding phosphorylcholine fall into three 
groups that correlate with various "subspecificities." Accord-
ingly, we postulate that the light chain can play an important 
role in "fine tuning" the specificity of the inununoglobulin 
molecule. 
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The amino acid sequence analyses of homogeneous myeloma 
immunoglobulins from a variety of mammals have provided impor-
tant insights into the structure, genetics, regulation and 
evolution of immunoglobulins(l). The immunoglobulin molecule 
is composed of light and heavy chains each of which can be 
divided into a highly variable (V) region and a more conserved 
constant (C) region. The variable regions of both the heavy 
and light chains determine antigen-binding specificity of the 
molecule and exhibit segments of extreme diversity termed 
hypervariable regions( 2 , 3 ). Two of the three hypervariable 
regions in the light chain and three of four in the heavy chain 
form the walls of the antigen-binding crevice( 4 ). 
Myeloma tumors can be artificially induced in the inbred 
strain of mouse BALB/c by intraperontoneal injections of min-
eral oil or similar compounds(S). These tumors represent many 
different classes of immunoglobulins and can be frozen for 
storage or transplanted to many additional BALB/c mice to 
produce virtually unlimited quantities of any given immuno-
globulin. Banks with thousands of different tumors have 
been developed in several laboratories and are available for 
study( 6 ), thus it is now possible to examine vast numbers of 
immunoglobulins produced by a single genome. Large numbers of 
these proteins have been screened for hapten-binding activity 
and approximately five percent bind specifically to one or more 
of a series of haptens including phosphorylcholine, 2+1 and 
2+6 levans, 1+3 and 1+6 dextrans, 1+6 galactan, and Dnp. Two 
lines of evidence indicate that these myeloma proteins represent 
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the normal immunoglobulin population. First, BALB/c myeloma 
tumors arise in the gut cavity and presumably represent trans-
formed lymphocytes from expanded clones of antibody-producing 
cells directed against gut antigens. Many of the haptens which 
bind to the myeloma proteins are found on the normal gut flora 
in BALB/c mice. Second, antibodies can be raised that are 
highly specific for the variable regions of myeloma proteins. 
The collection of unique antigenic determinants on a particular 
myeloma protein recognized by this antisera is termed its 
idiotype. The idiotype of certain myeloma proteins which bind 
phosphorylcholine and 1~3 dextran are indistinguishable from 
the idiotypes of the antibodies normally induced in the BALB/c 
mouse against these antigens '(?,S). This observation suggests 
that the structure of the myeloma protein is very similar, if 
not identical, to the structure of the normally induced antibody. 
Our laboratories have recently initiated an analysis of 
the structure-function relationships of sets of myeloma proteins 
binding identical or related haptens. Initial studies of the 
light and heavy chains from five myeloma proteins binding phos-
phorylcholine demonstrated that the heavy chains were virtually 
identical through the first hypervariable region, whereas the 
light chains differed up to 50% of their N-terminal sequences( 9). 
A study of the N-terminal regions of 28 heavy chains from mye-
lo~a proteins binding various haptens has confirmed the striking 
conservation of heavy chain sequence among myeloma proteins 
binding a common hapten(lO). This paper reports additional 
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N-terminal VH and VL sequences of proteins which bind various hap-
tens and compares the sequence conservation found in each subunit 
within a specificity. The variation of VL regions is discussed 
with respect to the chemical nature of the hapten and the con-
cept of "fine tuning" immunoglobulin specificity. 
Myeloma tumors were grown in BALB/c and CDFl mice. The 
. 1 b l' . . b . . (11) 1mmunog o u ins were purified y affinity chromatography 
or as indicated in (10). Light and heavy chains were separated 
(10,12? and analyzed on a Beckman 890A sequenator as previously 
described (10) • 
The sequence data can be summarized by use of a genealogical 
tree. This tree is a graphic representation of the minimal 
number of genetic events required to generate this set of se-
quences from a single ancestral gene. The number of base 
mutations required is depicted by distance along the lines 
joining two proteins. 
A genealogical tree generated from the amino terminal 20 
residues from all heavy chain sequences available as reported 
in (_10} is shown in Fig. 1. The heavy chains from molecules 
of similar hapten-binding specificity are located on closely 
related branches of the tree, indicating a great deal of se-
quence homology. 
The light chain sequences from these molecules is shown in 
Fig. 2, and summarized in a genealogic tree based on the amino 
terminal 23 residues in Fig. 3. Two degrees of sequence restric-
tion are apparent. For the carbohydrate specificities, namely 
a(l+3) dextran, a(l+6) dextran, and (271) levan, the light 
95 
Fig. 1.--Genealogical tree generated from the N-terminal 
20 residues from BALB/c myeloma heavy chains. The data for 
this tree are from (10). The minimum mutational distance 
between two sequences is represented by the distance along 
the lines {branches) which join them. The numbers along 
each branch denote the actual mutational distance. The 
abbreviations under each tumor number indicate the hapten-
binding activity of the intact immunoglobulin and are: Dnp, 
dinitrophenyl; SAU, 5-acetyluracil; l,3D, a(l+3) dextran; 
l,6D, a(l+6) dextran; l,6G, 8(1+6) galactan; 2,lL, S(2+1) 
levan; 2,6L, 8(2+6) levan; and TMA, trimethylamine. 
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Fig. 2.--N-terminal sequences from light chains which 
bind phosphorylcholine and levans. Spec. denotes the hapten-
binding specificity of the intact molecule. Binding speci-
ficity abbreviations are the same as in Fig. 1. The proto-
type sequence represents the most common amino acid at each 
position when all available BALB/c kappa chain sequences 
are examined. Lines indicate sequence identity with the 
prototype. Letters indicate the amino acids using the single 
letter code: A, alanine; B, asparagine or aspartic acid; 
C, cysteine; D, aspartic acid; E, glutamic acid; F, phenyl-
alanine; G, glycine; H, histidine; I, isoleucine; K, lysine; 
L, leucine; M, methionine; N, asparagine; P, praline; 
Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; 
W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid. 
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Fig. 3 . --The geriealogical tre~ from the N-terminal 
23 residues of light chains from BALB/c myeloma proteins . 
Sequences are from (13, 14, 15, and 16) and Fig . 2. Ab-
breviations are the same as in Fig . 1. 
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chains are all highly conserved in sequence much like the 
a(l+6) galactan specificity reported previously (12). For the 
noncarbohydrate specificities dinitrophenyl and phosphorylcholine, 
a great deal of flexibility of light chain sequence exists. 
These two categories of VL sequence restriction can be explained 
by the nature of the hapten involved. 
The carbohydrate binding myeloma proteins show maximum 
affinity for molecules ranging in size from trimers to hexa-
mers (l 7). These oligomers must bind in a highly complementary 
fashion to the antigen-binding site since their major inter-
actions must involve hydrogen binding of the sugar's hydroxyl 
groups and van der Waals interactions. Since the carbohydrate 
moiety is rigid, it is unlikely that a large proportion of 
the hydroxyl groups line up in a linear fashion with appro-
priate groups on the protein necessary to give strong inter-
actions. A great deal of molecular complementarity is also 
required for van der Waals interactions, analogous perhaps to 
h b b . . (18) . t e car ohydrate ind1ng to lysozyme • Accordingly, there 
is little room for variation in the active site and the VL and 
VH regions would be expected to be highly conserved. 
In contrast, dinitrophenyl and phosphorylcholine are small 
haptens which have polar groups available for relatively strong 
ionic interactions. In addition, the dinitrophenyl group has 
pi electrons available for charge transfer interactions with 
aromatic side chains of the immunoglobulins. Thus, these moieties 
should be able to bind to the active site in a variety of dif-
ferent configurations employing a few strong noncovalent bonds. 
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The VL region sequences from phosphorylcholine-binding 
myeloma proteins correlate with three distinct subspecificities 
(19) 1) Proteiris TlS, HB, and Sl07 bind phosphorylcholine 
much more :tightly than either choline or phosphonocholine. 
2) M511 and Ml67 bind choline nearly as well as phosphorylcholine, 
but do not bind phosphonocholine tightly. 3) M603 binds phos-
phonocholine very well. The VL sequences within each subspec-
ificity are highly similar. (Fig. 2). VL regions from Tl5, H8, 
and Sl07 are identical for their N-terminal 40 residues. VL 
regions from M511 and Ml67 differ by only two residues in the 
first 23, yet they are very different from light chains of the 
other two subspecificities. Finally, the VL region from M603 
is quite distinct from those of .the other subspecificities. In 
this regard, it is intriguing that W3207 possesses a light chain 
very similar to M603, but has not been well characterized with 
regard to its subspecificity. Accordingly, it appears that the 
light chain diversity in myeloma proteins binding phosphorylcholine 
correlates with the subspecificities of the respective molecules. 
Hence the light chains may play a role in "fine tuning" the more 
general specificity of the heavy chain. In view of this hypo-
thesis, we expect that 3207 will possess a M603-like subspeci-
ficity. 
Three of these proteins are idiotypically identical (TlS, 
HB, and Sl07), implying a high degree of structural similarity. 
The idiotypes for M603, Ml67, and M511 are distinct from each 
other and from those of the Tl5 group(s ) • W3207 has not been 
well characterized with regard to idiotype, although it differs 
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from Tl5( 20j . As additional structural data are gathered it 
will be possible to determine which structural features of VL 
and VH regions correlate with the idiotype. 
These results place two important constraints on theories 
of antibody diversity. First, the diversity of VL regions of 
each subspecificity within the myeloma proteins that bind phos-
phorylcholine is so great that the corresponding sequences must 
be coded by separate VL genes unless one concedes extensive par-
allel mutation(l) . Second, the correlation of structure out-
side the hypervariable region (i.e., framework residues) with 
antigen-binding specificity renders unlikely one recently pro-
d h f . b d d. . <21 ) . 1 f f h. pose t eory o anti o y iversity . A simp e orm o t is 
theory proposed that the framework and hypervariable regions are 
coded by separate genes in the germ line and that the hyper-
variable genes are inserted into the framework gene to generate 
a complete V gene during differentiation. This view is based in 
part on the belief that only the hypervariable regions determine 
antigen-binding specificity since the framework regions are 
remarkably invariant in their tertiary structure( 4 ). If this 
theory is correct, a given set of hypervariable regions (i.e., 
those coding for Dnp binding) should be able to insert into any 
framework sequence to generate a Dnp antibody. Since the VH 
and some VL framework sequences correlate very well with their 
corresponding antigen-binding specificities, this theory of 
episomal insertion requires additional unattractive ad hoc 
assumptions . 
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The observation that many myeloma idiotypes (e.g., Tl5) can 
be found in normally induced antibodies has permitted the fine 
structure genetic mapping of these determinants<22J. These 
idiotypes are expressed on normal antibodies found in some but 
not all strains of inbred mice and are inherited as a dominant 
gene. Preliminary genetic studies indicate that the idiotypes 
are all linked to one another and to the CH genes. Why these 
idiotypes are linked only to the CH and ·presumably VH regions is 
an intriguing question. Is the idiotype reflecting only VH 
region determinants? Will the various idiotypes expressed in 
the molecules which bind phosphorylcholine map together or 
apart? Is there any correlation between the various branches 
on the genealogical tree and the VH genetic map? Answers to 
these questions will have important implications for theories 
of antibody diversity. 
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SUMMARY 
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SUMMARY 
The immune system is an excellent model with which to study 
one of the major evolutionary steps required to generate the 
complex organisms which exist today. To generate higher eukar-
yote, it was necessary to evolve a system for cell recognition 
and cooperation. Such a system required a high degree of spec-
ificity and diversity, probably manifested as different cell 
surface receptors. The genetic mechanisms responsible for anti-
body diversity and specificity most likely evolved from such 
a receptor system. By examining a series of gene products from 
imrnunoglobulins, we may learn more about the mechanisms opera-
ting in the immune system as well as in other complex mammalian 
systems. 
The current data suggest fewer antibodies exist than was 
believed. Recent data from several sources suggest that the 
antibody population does not consist of a nearly infinite number 
of proteins. Work by Richards et al (42) has shown that the same 
immunoglobulin can bind to several similar haptens and even to 
a few which differ greatly in structure. This indicates that 
the antibody combining site is not monospecific. This concept 
is more consistent with observations on other macromolecular 
systems (e.g., the proteolytic enzymes) :(43). A decrease in the 
specificity of the antibodies correspondingly reduces the diver-
sity requirement for the system. 
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A second indication that the functional diversity observed 
in a response is more restricted than previously believed is 
the idiotypic studies on natural antibodies made to phosphoryl-
choline (PC) and a(l+3) dextran (l,3D). The majority of anti-
bodies made to these two antigens are each very restricted in 
idiotype. Our sequence studies have shown that the idiotypes 
represent molecules with a large degree of sequence similarity 
or identity in the variable regions. This suggests that there 
is a "best fit" molecule for many antigens and this molecule 
predomlnates after repeated exposures to the immunogen. Since 
PC and l,3D represent common natural antigens encountered by 
the BALB/c, the concept of extremely diverse antibody responses 
to nearly any hapten is now questionable. The original response 
may be heterogeneous due to cross reactivity analogous to that 
noted by Richards, but hyperimmunization greatly decreases the 
heterogeneity observed. 
One example of this phenomenon is the dini trophenyl response 
in Guinea pigs (44). Dinitrophenyl has classically been used 
as an immunogen since it gives a very large heterogeneous anti-
body response. This hapten is capable of forming relatively 
strong non-specific interactions with proteins and thus the 
active site structural requirements to generate a binding affinity 
capable of stimulating antibody production are quite small. 
This allows a large number of different antibody-producing 
clones to be expanded out early in the response. Hyperimmuni-
zation with this hapten greatly reduces this heterogeneity 
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however, at least in the heavy chain variable region. Since 
the DNP molecule can bind to such a large number of different 
antibodies and myeloma proteins (15) through quite non~specific 
interactions, it is questionable how representative such a 
response is of that to natural antigens. 
Our studies on the molecular subunits from myeloma proteins 
also indicate that immunoglobulins which bind to any determinant 
examined are all highly restricted in their heavy chain struc-
ture. In some specificities, the light chain sequence is simi-
larly c9nserved. This again indicates that natural antibodies 
made in response ,to a hapten are quite restricted in structure. 
Since the antibodies are not monospecif ic and since the 
response to many antigens seems to be restricted as to the num-
ber of different antibodies produced, it seems that 10 5 dif-
ferent specificities may be sufficient for maintaining the 
creature. Still, this is a large number of different molecules 
and new genetic mechanisms were required during evolution to 
provide this diversity. 
Mixing a ser~~s of gene products to form different mole-
cules was imperative to generate the antibody system. The 
major obstacle in evolving a very diverse system like that for 
antibodies was the amount of DNA a creature could afford to 
commit to the purpose. If an organism committed a single gene 
for each specificity, 105 different specificities would require 
10 5 different genes, each of which contained 675 base pairs or 
more (1 V + 1 VL == 225 AA = 675 base pairs). This would represent 
. H 
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an extremely larqe genetic load to the animal. In order to 
provide the 105 or more different antibody active sites, it 
was necessary to encode the site in two halves, one in the 
heavy chRin and one .:i.n the light chain. By combining various 
heavy and light chains to form different active sites, the 
creature could drastically reduce the amount of germ line DNA 
required. To maximize the advantage derived from encoding the 
active site in two parts, the variable regions of the light 
and heavy chains must be equally diverse. One million different 
molecules can be generated from 2000 V genes if each subunit 
library contains 1000 genes. If the VH library was only 1% as 
diverse as the VL library, 10,100 genes would be required to 
generate the 10 6 VHVL pairs. Our data on the BALB/c myeloma 
heavy chains suggest that indeed the heavy and kappa chains 
are comparably diverse. This again is consistent with the con-
cept of encoding the functional diversity in germ line genes. 
Correlation of amino acid sequence and binding . affinity 
reduces the somatic contribution to diversity. When we selected 
subset~ of immunoglobulins based upon their function, i.e., 
binding characteristics, we found that the variable regions 
within hapten-binding spBcificities represent one or more unique 
germ line genes unless one accepts an extremely large rate of 
parallel mutation. Within phosphorylcholine-binding proteins, 
three subsets of light chains exist which must be encoded 
by at least three germ line V genes. The heavy chains appear 
to be encoded by at least four germ line genes which differ from 
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any other VH genes found to date. If somatic mutation con""' 
tributed a major role in generating antibody diversity and 
specificity, the active site structure would be expected to 
correlate much more closely in sequence to the hapten-binding 
activity than would the framework regions. Indeed, if somatic 
mutation operated at a high level, from a few genes a high degree 
of sequence flexibility should appear in the framework regions. 
In fact, we find just the opposite; the framework regions are 
highly conserved, thus a large amound of the structure must 
be encoded in the germ line. 
One explanation: After four years of studying irnmunoglo-
bulin structure, I believe that the model which best explains 
the current data is one in which there is nothing magic about 
the structure of the antibody molecule itself. The antibody 
population is a collection of 10 5 or more proteins which have 
active sites analogous to enzymes. Each molecule must cross 
react with a series of similar haptens. The information for 
the antibody subunits is encoded in the germ line·of the animal 
and selection for function must occur during evolution. The 
primary structure of the heavy and light chain variable regions 
determines the specificity of the molecule and there is no 
reason to believe that somatic mutation contributes to the 
functional diversity. The hypervariable regions are probably 
under different evolutionary selective pressures and thus mu-
tate at a higher rate--analogous to the outer surf ace residues 
of cytochrome c (45) • The number of different V genes in the 
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kappa and heavy chains is comparable and probably greater than 
1000. If only 10% of the VHVL combinations are functional, 
it could generate sufficient diversity to combat most potential 
pathogens encountered during evolution. 
As with most fields of biology, however, each answer or 
partial answer to a question generates many additional questions. 
Now that it appears certain that the antibodies represent a 
large multigene system, many new questions relating to the con-
trol mechanisms which must exist to govern gene expression within 
VH and VL libraries have arisen. During ontogeny is the readout 
of variable regions programmed? Which is committed first, VH 
or VL? How does a creature generate 10 5 different antibody-
producing clones in such a very ,short time? Is there a genet~ 
ic mechanism which restricts the expression of various VH 
a V . ? an L pairs. 
Th~se and many other questions will continue to make the 
investigation of antibody diversity extremely active and intri-
guing . As a model for multigene systems, the antibodies should 
provide principles applicable to differentiation. As part of 
nature's prime method of protection from microorganisms for 
higher creatures, it will provide valuable therapeutic infor-
mation if we can learn how to manipulate the system. Each new 
finding will again generate many more questions, keeping this 
field one of the most exciting areas in molecular biology for 
some time to come. 
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